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ABSTRACT
Singh, Richa, M.S., Microbiology and Immunology Graduate Program, Wright State University,
2013. N-Glycosylation, Localization and Trafficking of Endogenous NKCC1in COS7 cells

The Na+K+2Cl– co-transporter-1 (NKCC1) effects the electroneutral movement of Na+,
K+ and 2Cl– ions across plasma membranes. NKCC1 is considered a widely distributed, highly
N-glycosylated ion transporter involved in the regulation of the intracellular chloride
concentration ([Cl–]i), cell volume and salt secretion. NKCC1 locates in the plasma membrane of
all cells studied so far, particularly on the basolateral side of most polarized cells. However, the
majority of immunoreactive NKCC1 distributes in intracellular compartments of unknown nature
whereas a small proportion of the transporter appears to be located in the plasma membrane.
Here, we identified and characterized the molecular expression pattern of NKCC1 in the monkey
kidney fibroblast-like cell line COS7 and determined the impact of N-glycosylation on the
cellular distribution of endogenous NKCC1 in these cells. We show that one of the two splice
variants of NKCC1 i.e., NKCC1a is expressed in COS7 cells as a core/high-mannose/hybrid and
complex N-glycosylated form in an approximate 4:1 ratio. Moreover, we demonstrate that
NKCC1a locates in endoplasmic reticulum, medial-Golgi cisternae and recycling endosomes but
minimally at the plasma membrane. We estimated that ~5-10 % of total NKCC1a expressed in
COS7 cells reaches the plasma membrane in a functional state and in a comparable core/highmannose/hybrid to complex N-glycan proportion as the one observed in total extracts suggesting
that N-glycosylation of NKCC1a is not a steady state signal for plasma membrane targeting of
the transporter. Further, treatment of cells with tunicamycin, a potent inhibitor of the first step of
N-glycan biosynthesis, results in endoplasmic reticulum retention and decreased total and plasma
membrane located NKCC1a protein expression levels without affecting the ratio between
III

core/high-mannose, hybrid and complex N-glycosylated NKCC1a, indicating that the N-glycan
nature of NKCC1a depends on its biosynthesis. Moreover, inhibition of N-glycan
processing/maturation with kifunensine or swainsonine decreased basal complex N-glycosylated
NKCC1a expression but increased basal expression levels of core/high-mannose/hybrid Nglycosylated NKCC1a at the plasma membrane, confirming that NKCC1a is delivered to this
compartment independently of the N-glycan nature of the transporter. Altogether, our results are
consistent with the conclusion that most of endogenous NKCC1a locates in defined intracellular
compartments and that the N-glycan nature of the transporter does not dictate trafficking of the
transporter from one compartment to another, but rather reflects the biosynthetic pathway of the
protein.
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1. INTRODUCTION
The intracellular chloride concentration ([Cl–]i) plays key physiological and cellular
functions including, but not limited to the regulation of the intracellular ionic environment, cell
volume, transepithelial ionic transport, cellular excitability, cell migration, cell proliferation and
differentiation, hormone secretion and stabilization of membrane potential (Alvarez-Leefmans
2012; Najvirtova, et al. 2003). In most cells, Cl– ions are actively transported by a group of
proteins, creating an intracellular chemical gradient, which in turn is dissipated by Cl– channels.
It is this gradient of Cl– ions which plays key roles in physiology. This is dramatically illustrated
in several human inherited disorders or genetically engineered mice where dysfunction or
absence of one or several Cl– transporters or channels leads to clinical or phenotypic
manifestations characteristic of Bartter’s, Gordon's, Andermann’s syndromes, cystic fibrosis,
Dent's disease, myotonia congenita and many other human conditions [reviewed in (Alper and
Sharma 2013; Arroyo, et al. 2013; Romero, et al. 2013)].
As stated previously, Cl– channels and transporters play pivotal roles in regulating and
maintaining the ionic composition of the cytoplasm and the cell volume [reviewed in (AlvarezLeefmans 2012)]. In addition, the close functional interplay between Cl– transporters and
channels with other ionic transporters or pumps results in the overall regulation of fundamental
physiological parameters within the cell. For instance, intracellular pH is tightly regulated by
Na+/H+ and H+CO3–/Cl– exchangers, which require parallel Cl– movement in or out of the cell
(Alper and Sharma 2013; Romero et al. 2013). Additionally, cells may also use ATPases along
with Cl– channels to maintain electro-neutrality, a mechanism used similarly for acidification of
several intracellular compartments (Romero et al. 2013).

1

The [Cl–]i is required for salt, water and ion transport across cellular epithelia (D'Andrea,
et al. 1996; Evans, et al. 2000; Flagella, et al. 1999; Frizzell and Hanrahan 2012; Hoffmann, et
al. 2007; Ko, et al. 2002; Wehner, et al. 2003). In fact, expression of Cl– channels in the apical
membrane of polarized epithelia coupled with the active uptake of Cl– at the basolateral side of
the polarized cell ensures directionality of the ion flux resulting in vectorial movement of salts
and water across the epithelia. For instance, acinar cells of several secretory glands such as the
airway, pancreatic, salivary or intestinal epithelia actively secrete Cl– to the luminal side (Frizzell
and Hanrahan 2012). This vectorial movement of Cl– is possible because Cl– transporters set and
maintain [Cl–]i above electrochemical equilibrium, i.e., an intracellular concentration higher than
the one predicted by the Nernst equation, a characteristic of most of secretory epithelia (Frizzell
and Hanrahan 2012). In non polarized epithelia such as neurons and some electrically excitable
cells, high [Cl–]i plays important functions in plasma membrane excitability which eventually
leads to regulation of neurotransmitter or hormonal release as well as their actions or signaling
(see Sections 1.8 and 1.10).

1.1

The SLC12A family of genes, nomenclature and classification
Many Cl– transporters are directly involved in keeping or regulating [Cl–]i in cells. These

include mainly members of the solute carrier (SLC) superfamily 12, 4 and 25 [SLC12A, SLC4A
and SLC26A, reviewed in (Alvarez-Leefmans 2012)]. In the next sections, we will concentrate on
the SLC12A family of genes, which contain at least seven homologous transporters involved in
net Cl– movement either in or out of the cell. This group, also known as the cation-chloridecotransporters (CCCs), may be subdivided into three main branches based on sequence identity
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and functional properties (Figure 1). These are: Na+K+2Cl–, Na+Cl– and K+Cl– cotransporters,
i.e., NKCCs, NCCs and KCCs, respectively (Di Fulvio and Alvarez-Leefmans 2009; Gagnon
and Di Fulvio 2013). It is important to note that there is a potential fourth group within this
family which is represented by two SLC12A members of unknown or partially defined function
or transport capabilities i.e., SLC12A8 (CCC9) and SLC12A9 (CIP1). Although the predicted
protein sequence encoded by these genes do not have enough sequence identity to be considered
part of the SLC12A family i.e., less than 25% (Di Fulvio and Alvarez-Leefmans 2009; Gagnon
and Di Fulvio 2013), it is still relatively common to include them as part of the family (Gagnon
and Delpire 2013; Hebert, et al. 2004) in spite of the fact that CCC9 or CIP1 do not transport Cl–
but polyamines and certain amino acids, at least in the case of CCC9 (Daigle, et al. 2009).
Clearly, sequence identity may not be a sole indicator of gene homology and additional
confirmatory work needs to be done in order to include/exclude CCC9/CIP1 in the SLC12A
family of genes.
The accepted nomenclature of the SLC12A transporters of the three main groups is as
follows: SLC12A2 (NKCC1), SLC12A1 (NKCC2), SLC12A3 (Na+Cl– co-transporter, NCC) and
SLC12A4-7 (K+Cl– co-transporters, KCC1-4) (Figure 1). All of these transporters have been
extensively characterized at the functional level, mostly in heterologous expression systems such
as the Xenopus laevis oocytes (Gamba 2005). The focus of our research involves one member of
the SLC12A family of transporters i.e., NKCC1 and therefore, the next sections deal mainly with
the molecular and functional properties of this transporter, making reference to other members in
a comparative manner when needed. For detailed analysis of all members of the SLC12A family,
the reader is directed to latest specialized reviews written by experts in the field (AlvarezLeefmans 2012; Arroyo et al. 2013; Hediger, et al. 2004).
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Figure 1. Cladogram tree relating members of the SLC12A
family of genes. The branching shown was generated by
neighbor-joining analysis using the genetic distance model
developed by Jukes & Cantor (Evolution of Protein Molecules.
New York: Academic Press. pp. 21–132, 1969) and included in
the software suite Geneious R6 (Biomatters Ltd. NZ)
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1.2.

The SLC12A2 gene and its splice variants
The human gene encoding NKCC1 (SLC12A2) encompasses 27 exons and introns placed

in 75 kb of genomic DNA in the human chromosome 5 (Di Fulvio and Alvarez-Leefmans 2009;
Payne and Forbush 1995). This gene produces at least two splice variants of NKCC1 with
variable degree of expression in different organs, cells or tissues and subtle molecular differences
among species (Table I). For instance, mouse and rat Slc12a2 genes produce the variants
NKCC1a (NM_009194 and NM_031798, respectively) and a shorter version lacking the 21st
exon (Randall, et al. 1997), named here and in recent reviews NKCC1b (Alvarez-Leefmans
2012). The human (h) SLC12A2 gene produces at least three splice variants: hNKCC1a
(U30246, AY280459) (Liedtke and Cole 2000; Payne and Forbush 1995), hNKCC1b
(BC144221 and BC146839) and hNKCC1c (BC033003). Two coding exons are involved in the
generation of these hNKCC1 variants: exon 21 and exon 26 [reviewed in (Di Fulvio and
Alvarez-Leefmans 2009)]. For example, as in mouse or rat NKCC1, absence of exon 21 in
hNKCC1 mRNAs gives rise to hNKCC1b (Figure 2). Human NKCC1c, however, is the result of
the election of an internal splicing site located in the 26th exon of the human SLC12A2 gene. This
internal splicing acceptor site divides exon 26 into two coding parts named exon 26A (66 bp) and
26B (68 bp). Inclusion of the entire exon 26 (A + B = 134 bp) generates hNKCC1c. The
hNKCC1c cDNA sequence predicts the translation of an 1151 amino acid protein with a unique
C-terminal sequence (FYEPC). NKCC1b has been detected in several tissues and cells (Mao, et
al. 2012; Randall et al. 1997) and its functional properties appear not to differ from NKCC1a, at
least when these transporters are constructed in vitro and overexpressed in cells (Vibat, et al.
2001). The expression pattern and functional roles of hNKCC1c, however, are unknown.
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Table I. NKCC1 variants in mammals
Species

Name

mRNA#

Protein #

Human

NKCC1a

NM_001046

NP_001037

NKCC1c

U30246
AY280459
NM_001256461 NP_001243390 BC144221
BC146839
NR_046207
non-coding?
BC033003

T84 cell line
Calu-3 cell line
Pooled tissues
Testis
Testis

Cow

NKCC1a

NM_174782

NP_777207

U70138

Aorta

Mouse

NKCC1a
NKCC1b

NM_009194
-

NP_033220

U13174
-

mIMCD-3 cell line

Rat

NKCC1a
NKCC1b

NM_031798
-

NP_033220

AF051561
-

Parotid gland

Mole rat

NKCC1a
NKCC1b

-

-

JL987661
JL987662

Muscle, brain
Muscle, brain

Tuco-tuco NKCC1a
NKCC1b

-

-

JU567365
JU567366

Hypocampus
Hypocampus

Hamster

-

-

XR_136059

CHO-K1 cell line

NKCC1b

NKCC1a

cDNA@

Source*

# Transcripts or protein identity number annotated in RefSeq database i.e., a collection of curated
transcript sequences generated in silico based on published or experimentally determined cDNA
sequences.
@ Clone identity as posted in GenBank database corresponding to full-length cDNA sequences
cloned in laboratories.
* Source of full-length cDNA clones, the most reliable proof of gene expression.
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A

0

5kb

Gene SLC12A2 (NKCC1 chromosome 5)

21

NKCC1a
NKCC1b

B

SLC12A2 exon 20

SLC12A2 exon 21 spliced out in NKCC1b

SLC12A2 exon 22

NKCC1a

GAAAAA CCAAUUA CA CA CAAAGUUGAGGAAGAGGAUGGCAAGA CUG CAACUCAA CCACUGUUGAAAAAAGAAUCCAAAGGCCCUAUUGUGCCUUU
E K P I T H K V E E E D G K T A T Q P L L K K E S K G P I V P L

NKCC1b

GAAAAA CCAAUUA CA CA CAAAG.................................................... AAUCCAAAGGCCCUAUUGUGCCUUU
E K P I T H K
E S K G P I V P L

Figure 2. The human NKCC1 (SLC12A2) gene. A. Represented is the genomic organization of the human SLC12A2
gene as depicted in AceView database (www.ncbi.nlm.nih.gov/IEB/Research/Acembly). The 27 exons constituting the
gene are shown as boxes and the 21st exon involved in splicing as a red boxe. 5’- and 3’-untranslated regions are shown as
open boxes. B. Representation of the splicing event involving exon 21 (red) and the amino acid sequence predicted to
be eliminated upon splicing.
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1.3.

Functional properties of NKCC1
NKCC1 effects the electrically neutral transport of Na+, K+ and Cl– ions across cellular

membranes in a stoichiometry of 1Na+:1K+:2Cl– ions in most if not all cases (Alvarez-Leefmans
and Delpire 2009; Russell 2000). Although the net transport of ions may occur either in or out of
the cell depending upon the sum of the chemical gradients of the transported ions, in most cells
under physiological conditions the transport of ions through NKCC1 occurs from the
extracellular medium to the cytoplasm (Alvarez-Leefmans 2012). Numerous studies have
demonstrated that NKCC1 plays a key role in cellular ion homeostasis, i.e., in keeping [Cl–]i
above electrochemical equilibrium and cell volume regulation in all cells where NKCC1 is
expressed (Hoffmann, et al. 2009). As mentioned, it is the thermodynamically high [Cl–]i in cells
that makes possible the synaptic properties of some neurotransmitters (see Section 1.8), salts and
water transport across epithelia and hormone secretion (discussed in Sections 1.6 and 1.10,
respectively).

1.4.

Molecular characteristics of NKCC1 proteins
Hydropathy analysis of the predicted amino acid sequences of NKCC1a suggests three

distinctive regions in the protein: two large hydrophilic N- and C-termini (15-35 and ~50 kDa,
respectively) and a central hydrophobic domain containing at least 12 transmembrane (TM)
domains (~50 kDa) (Gerelsaikhan, et al. 2006; Gerelsaikhan and Turner 2000a, b; Payne, et al.
1995) (Figure 3). The N-terminus of NKCC1 has the lowest amino acid identity among the three
regions while its C-terminus is highly conserved among species ranging from cyanobacterium,
yeast to humans. The TM segments 1-8 consist of ~20 residues in !-helix configuration whereas
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Figure 3. Predicted protein topology of NKCC1a. The protein topology of NKCC1a
is believed to consist of two large intracellular N- and C-termini, and 12
transmembrane domains interconnected with intracellular or extracellular loops of
variable lenghts. The fourth extracellular loop connecting transmembrane domains 7
and 8 contains two predicted N-glycosylation sequons (depicted in red). The long
intracellular C-terminus contains the residues encoded by exon 21 (depicted in blue).
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TM 9-12 includes ~36 residues forming either hairpin-like or partial helical structures. Although
predicted in silico, this topological analysis of NKCC1 is experimentally supported by the
studies of Parvin, Gerelsaikhan and collaborators (Gerelsaikhan et al. 2006; Gerelsaikhan and
Turner 2000a, b; Parvin, et al. 2007). The high degree of identity between NKCC1, NCC and
NKCC2 being more than 60% suggests that the topology of these transporters might be similar.
However, in the absence of crystal structures, the definitive molecular shape of the transporter is
still debatable (Di Fulvio and Alvarez-Leefmans 2009). Contrary to the functional properties of
the C-terminus, which remain unclear, the ability of the N-terminal region of NKCCs to regulate
the function of the transporter is relatively well defined. Indeed, the N-terminus of NKCC1
contains several predicted phosphorylation sites, most of them considered mapped and
functionally characterized [(Arroyo et al. 2013) see Section 1.12]. These sites are conserved
among members of the SLC12A family and therefore are predicted to have similar acute
regulatory roles in NKCCs and NCCs. In addition to the presence of phosphorylation sites in the
amino acid sequence of NKCC1, the transporter has two predicted N-glycosylation sites in the
extracellular loop interconnecting TM domains 7 and 8 (Figure 3). One or both of these sites are
N-glycosylated in vivo, as demonstrated in immunoblotting experiments coupled to enzymatic
de-glycosylation experiments performed in a wide variety of cells and tissues (AlvarezLeefmans, et al. 2001; Gerelsaikhan et al. 2006; Gerelsaikhan and Turner 2000a, b; Kaplan, et al.
1996; Marty, et al. 2002; Moore-Hoon and Turner 1998, 2000; Nezu, et al. 2009; Payne et al.
1995; Plotkin, et al. 1997) (see Sections 1.13 and 1.14). The impact that these N-glycosylation
residues may have on the functional, pharmacological or molecular properties of NKCC1 still
remain to be determined.
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1.5.

Tissue distribution and cellular localization of NKCC1
With some exceptions, including but not limited to tubular cells of the thick ascending

limb of Henle's loop (TALH) (Kaplan et al. 1996), !-cells of the endocrine pancreas i.e., islets of
Langerhans (Alshahrani, et al. 2012; Alshahrani and Di Fulvio 2012; Majid, et al. 2001),
NKCC1, has been found in all mammalian cells examined so far (Hoffmann et al. 2009).
Particularly, NKCC1 has been detected abundantly in the basolateral membrane of the rat
secretory coil cells, mouse and human sweat glands (Nejsum, et al. 2005), certain cells of the
stomach (Ji, et al. 2012; McDaniel and Lytle 1999) and other epithelia of the gastrointestinal
tract (Heitzmann and Warth 2008) as well as in non-epithelial tissues such as skeletal and cardiac
muscles (Kristensen and Juel 2010; Terashima, et al. 2006), sensory neurons and different
regions of the adult brain (Alvarez-Leefmans et al. 2001; Mao et al. 2012; Marty et al. 2002;
Munoz, et al. 2007). It is the particular basolateral location of NKCC1 that gave the name of
"secretory isoform" to this transporter [(Gamba 2005) see Section 1.7]. However, neither its
localization nor its function are shared in polarized cells of the choroid plexus where its location
is clearly apical (Plotkin et al. 1997) and may not perform "secretory" functions [reviewed in
(Brown, et al. 2009)]. Interestingly, careful analysis of published data clearly indicates that
NKCC1 locates extensively in intracellular compartments, regardless of the polarization nature
of the cells under study. Certainly, NKCC1 locates in intracellular compartments in the parotid
and shark rectal glands (Flemmer, et al. 2002), sensory neurons (Alvarez-Leefmans et al. 2001;
Mao et al. 2012; Mazzone and McGovern 2008; Pieraut, et al. 2007; Price, et al. 2006),
neuroendocrine cells (DeFazio, et al. 2002), neuroblasts (Mejia-Gervacio, et al. 2011), specific
neurons of the adult brain (Chen, et al. 2005; Marty et al. 2002; Plotkin et al. 1997) or cells of the
collecting ducts of the kidney (Kaplan et al. 1996). In fact, the non-exclusive plasma membrane
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distribution of NKCC1 appears to be the norm rather than the exception. In cell lines, for
instance, endogenous NKCC1 locates mainly in intracellular compartments of unknown nature
(Alshahrani et al. 2012; Alshahrani and Di Fulvio 2012; Majid et al. 2001; Nezu et al. 2009;
Payne, et al. 2001; Payne and Forbush 1995). Although the mechanisms involved in NKCC1
cellular localization are unknown at present, studies performed in cell lines led to the proposal
that N-glycosylation of NKCC1 plays a key role in plasma membrane targeting of NKCC1
(Payne et al. 2001), a concept that was partially confirmed for different transporters of the
SLC12A family (Benziane, et al. 2007; Hoover, et al. 2003; Zaarour, et al. 2011; Zaarour, et al.
2009; Zaarour, et al. 2012), but not for NKCC1.

1.6.

Pharmacological properties of NKCC1
NKCC1 is inhibited by 5-sulfobenzoic acid loop diuretics such as furosemide,

bumetanide, benzmetanide, piretanide, torsemide and other diuretics such as ethacrynic acid with
varying degrees of potency and in a fashion and efficiency highly dependent on the cell type,
tissue and species (Amsler and Kinne 1986; Cohen, et al. 1976; Haas and McManus 1983;
Halladay, et al. 1978; O'Donnell 1989; Petzinger, et al. 1989; Popowicz and Simmons 1988;
Rugg, et al. 1986; Ward and Heel 1984). Bumetanide (BTD), the most potent inhibitor of
NKCCs, binds plasma membranes with high affinity (Amsler and Kinne 1986; O'Donnell 1989;
Petzinger et al. 1989; Popowicz and Simmons 1988; Rugg et al. 1986). In fact, a proportion of
bound BTD might internalize, probably driven by its receptor i.e., NKCCs or other transporters
or proteins (Petzinger et al. 1989; Platte, et al. 1996). The chemical structure of BTD consists of
benzoic acid moiety, which at physiological pH circulates as a highly ionized compound
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therefore incapacitating the drug to freely cross plasma membranes (O'Donnell, et al. 2004).
When used at low concentrations BTD selectively and reversibly binds NKCC1 inhibiting its
transport activity with well-defined pharmacokinetic and pharmacodynamic characteristics in
mammals (Cohen et al. 1976; Flamenbaum and Friedman 1982; Gabriel and Baylor 1981;
Halladay et al. 1978; Halstenson and Matzke 1983; Schlatter, et al. 1983; Ward and Heel 1984).
BTD is a widely used diuretic, which actively blocks the reabsorption of Na+ and Cl– ions
in TALH affecting the transport of these ions across the membrane and therefore causing
excretion of Na+ and Cl– ions along with water, the main diuretic action of the drug
(Flamenbaum and Friedman 1982). This diuretic action of BTD is highly buffered by the ability
of plasma albumin to bind circulating BTD, the fast absorption time and its inactivation by
conjugation (Halladay et al. 1978). Nevertheless, intact BTD passes glomerular filtration and is
concentrated in the lumen of the tubules, particularly in the TALH where NKCC2 is abundantly
expressed (Ares, et al. 2011; Carota, et al. 2010; Castrop and Schnermann 2008) and, therefore
NKCC2 is considered the target of BTD in the kidney.
In virtue of its potent diuretic action, BTD is indicated for the treatment of edema caused
by congestive heart failure, liver or kidney disease and other related complications. Although the
most obvious pharmacological manifestation of BTD's action is the one that occur after targeting
NKCC2 in the kidney i.e., diuresis, very low doses of BTD (e.g., 10 !g/kg) do impact NKCC1mediated functionality in the brain decreasing neuronal [Cl–]i and promoting the inhibitory
actions of certain neurotransmitters such as GABA [(Edwards, et al. 2010) see Section 1.8]. In
doing so, BTD constitutes a promising therapeutic avenue for the treatment of neonatal seizures
(Khanna, et al. 2013; Loscher, et al. 2013). However, due to the wide distribution of NKCC1,
BTD may also impact the function of other systems, notably the one involved in hormone
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secretion (see Section 1.10).
Other loop diuretic and inhibitor of NKCCs such as furosemide is less applicable to treat
some pathological conditions whereas BTD is the drug of choice as its pharmacodynamic
potency is ~50 times less than furosemide and it is not completely absorbed in the intestine along
with varying differences in bioavailability (Brater, et al. 1983). Although furosemide is still in
use, other diuretics like piretanide or ethacrynic acid, drugs of intermediate efficacy between
BTD and furosemide, were used in the past to treat heart failure, hypertension or edema (Musini,
et al. 2012).

1.7.

Role of NKCC1 in fluid secretion
One of the best-known physiological roles of NKCC1 is related to salt secretion. Of

course, this function is accomplished by most but not all secretory epithelia (Alvarez-Leefmans
2012; Brown et al. 2009). In secretory epithelia of a wide variety of tissues including salivary
glands, sweat glands, stomach, trachea and pancreas, coordinated transport of ions occurs: Na+,
K+ and Cl– ions enter the cell through a basolateral transporter believed to be mainly NKCC1
whereas Cl– ions are channeled out of the cells into the lumen through apical Cl– channels such
as the cystic fibrosis transmembrane conductance regulator (CFTR) whilst K+ is taken up by
transporters and recycled back to the extracellular fluid via K+ channel and Na+/K+ pump. This
ionic movement generates a negative transepithelial Cl– gradient used by the cell to passively
drive Na+ ions into the lumen. Transporters like Na+/H+ and Cl–/HCO3– exchangers make use of
the inwardly transported Na+ ion to regulate influx of Cl– across basolateral membranes,
promoting the maintenance of [Cl–]i above thermodynamic equilibrium in these polarized
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epithelia (Frizzell and Hanrahan 2012).
The ionic equilibrium and secretion of cells of polarized epithelia are also impacted by
Ca2+ ions and its intracellular concentration i.e., [Ca2+]i. Indeed, Ca2+ mobilizing agonists such as
those targeting Ca2+ channels, Na+/Ca2+ exchangers, plasma membrane Ca2+-ATPases all
stimulate Cl– secretion by promoting K+ and Cl– permeability at the basolateral and apical sides
of the cells, respectively. Therefore, these agents trigger Cl– accumulation in the luminal side of
the plasma membrane (Lee and Foskett 2010). These Ca2+ mobilizing agonists also significantly
increase Na+/H+ exchanger activity as well as NKCC1 functionality (Baartscheer and van Borren
2008), consistent with the hypothesis that these transporters drive Cl– movement into the cells.
The entry of Na+ ions during this process is believed to neutralize and dissipate the
transepithelial negative potential generated by NKCC1-mediated accumulation of Cl– ions via
osmotic influx of water following in turn the NaCl gradient, resulting in secretion of hypotonic
saliva, for instance (Hille and Walz 2008). The importance of NKCC1 in secretion has been
validated in studies using mice lacking NKCC1. Indeed, mice deficient in basolateral NKCC1
have impaired Cl– secretion, severe hyposalivation (Evans et al. 2000) and are deaf, along with
exhibiting behavior indicative of inner ear defects (Delpire, et al. 1999; Flagella et al. 1999). The
impaired ear function of mice lacking NKCC1 is consistent with the high expression levels of
NKCC1 on the basolateral membranes of strial marginal cells and neurons of the inner ear
(Delpire et al. 1999).
As mentioned, NKCC1 role in Cl– uptake and secretion is not a universal phenomenon
found in all secretory epithelia. Indeed, gastric acid secretion in adults and intestinal fluid
secretion is not affected in mice lacking NKCC1, in spite of the fact that NKCC1 is abundantly
expressed in these tissues (Marshall, et al. 2002; McDaniel, et al. 2005). In addition, contrary to
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the general perception, no impaired pancreatic secretion in mice lacking NKCC1 has been
reported. It is important to mention that absence of NKCC1 early in embryogenesis may trigger
gene expression cascades with some compensatory functionality. Therefore, the phenotypes
observed in animal models lacking NKCC1 may actually reflect a myriad of new regulatory
cascades activated upon absence of NKCC1 rather than reflecting absence of NKCC1 per se,
making the interpretation of functional data difficult.

1.8.

Role of NKCC1 in GABAergic signaling
The amino acid "-amino-butyric acid (GABA) is considered the primary inhibitory

neurotransmitter of the adult central nervous system (CNS) (Alvarez-Leefmans and Delpire
2009). However, early in development of the CNS as well as in some neurons of the dorsal root
ganglion, GABA is typically excitatory. This is due to the fact that [Cl–]i in neurons is
developmentally regulated and that GABA-mediated activation of GABAA receptors i.e.,
channels with the highest permeability for Cl– ions (Ben-Ari 2002; Watanabe, et al. 2002)
provoke Cl– efflux or influx, depending on [Cl–]i. In immature neurons or nociceptors, [Cl–]i is
higher than thermodynamic equilibrium due to the predominant functional expression of Cl–uptake mechanisms i.e., NKCC1 over Cl–-extruding ones i.e., the product of the SLC12A5 gene
KCC2, whereas the opposite is observed in mature neurons (Rocha-Gonzalez, et al. 2008).
Therefore, activation of GABAA receptors promotes efflux of Cl– in immature neurons or
nociceptors with the consequent excitatory depolarization, a phenomenon that cannot occur in
mature neurons where [Cl–]i is found below thermodynamic equilibrium. Thus, GABAA
activation provokes influx of [Cl–]i in these cells, hyperpolarization and inhibition of their
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electrical activity [reviewed in extenso in (Alvarez-Leefmans and Delpire 2009)].
Clearly, [Cl–]i in neurons is determined by the functional balance between NKCCs, KCCs
and Cl– channels and therefore, it is [Cl–]i which gives GABA its inhibitory or stimulatory
properties. In fact, alterations of NKCC activity in brain have been linked to severe health related
disorders like epilepsy (Loscher et al. 2013; Reid, et al. 2000; Soul and Jensen 2010). Further, it
has been observed that application of BTD, one of the most potent inhibitors of NKCC1 known
to date, results in reduced seizure frequency in patients affected with temporal lobe epilepsy
(Eftekhari, et al. 2013).

1.9.

Role of NKCC1 in cell cycle progression
It has long been recognized that NKCC1 activity and [Cl–]i regulate cell proliferation

(Fiske, et al. 2006; Iwamoto, et al. 2004; Kunzelmann 2005; O'Brien, et al. 1988; Panet and
Atlan 1991; Panet, et al. 2006; Panet, et al. 2002; Panet, et al. 2000; Panet, et al. 1994; Payne et
al. 1995; Shiozaki, et al. 2006). Mechanistically, inhibition of NKCC1 or depletion of [Cl–]i
prevents cells' entrance to the S phase i.e., DNA synthesis (Ohsawa, et al. 2010). Early studies
have shown that the increased cell volume observed during proliferation is associated with
enhanced activity of NKCCs (Hoffmann et al. 2009). Indeed, as cells progress through cell cycle,
K+ and amino acid content usually double, reaching a peak soon before cell duplication
(Bussolati, et al. 1996). In support of the role of NKCC1 in cell proliferation, when the same
cells were treated with BTD for 24 hours, a 60% decrease in cell number relative to untreated
cells was observed (Bussolati et al. 1996). Similarly, treatment of rat pheochromocytoma PC12
cells with nerve growth factor resulted in increased activity of cotransport function and cell
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volume in a BTD-dependent manner (Leung, et al. 1994). These studies established that NKCC
activity is stimulated as cell passes from one stage of the cell cycle to another, further suggesting
that NKCC-mediated cell volume increase might be required for the cell to divide. Studies were
also performed on primary cell cultures, human fibroblast and bovine vascular endothelial cells
where the effect of BTD on the transition from G0 to G1 phases was studied measuring DNA
synthesis and cell number. In this study, it was observed that treatment with BTD inhibited
cellular proliferation suggesting a role of NKCCs in cell cycle progression (Panet and Atlan
1991). Recently, studies have shown that treatment with furosemide also reduced proliferation of
poorly differentiated cancer cells by affecting G0/G1 transition (Shiozaki et al. 2006). In addition,
overexpressed NKCC1 induces cellular proliferation and phenotypic transformation in mouse
fibroblast further emphasizing on the role of NKCCs in cell cycle progression (Panet et al. 2000).
All these studies support the hypothesis that NKCC1 plays a significant role in cell cycle and
thus this transporter may be targeted for developing therapeutics aiming to treat cancers.

1.10.

Role of NKCC1 in hormone secretion
The first observation leading to the recognition that NKCCs and [Cl–]i play an important

role in hormone secretion came from studies of ions and salt homeostasis in the neuroendocrine
system. Raichle and collaborators (1981) showed that vasopressin, angiotensin II and
norepinephrine secretion in the central neuroendocrine system is regulated by the ion
composition of the media surrounding the cells (Raichle 1981). Thereafter, several reports
supported the notion that NKCCs are involved in neurohormone release, a concept that was
confirmed in several species and neuroendocrine systems. In fact, studies published during the
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last forty years or so and performed in a non-neuroendocrine system such as insulin-secreting #cells of the islet of Langerhans of the pancreas have clearly implicated [Cl–]i and NKCCs in
glucose-induced depolarization of plasma membrane and insulin secretion [reviewed in extenso
in (Di Fulvio, et al. 2014)].
In general, the mechanism whereby glucose promotes insulin secretion involves plasma
membrane depolarization brought about sudden changes in the permeability of #-cells to K+ and
Cl– ions. Under physiological conditions, glucose stimulates insulin secretion using mainly the
well-characterized consensus KATP channel-dependent pathway. In this path, changes in
ATP/ADP ratios provoked by glucose metabolism within the #-cell leads to closure of these
channels, decreasing K+ conductance and causing depolarization of the membrane (Drews, et al.
2010). This glucose sensing mechanism is also linked to a poorly known, often ignored volumeactivated anion channels or to Cl– channels of unknown identity which promote Cl– efflux from
#-cells (Best, et al. 2010) in virtue of the high [Cl–]i demonstrated in these cells (Eberhardson, et
al. 2000; Kozak and Logothetis 1997). This Cl– efflux is heavily sensitive to BTD. In fact, BTD
inhibits insulin secretion at all concentrations of glucose tested so far (Alshahrani and Di Fulvio
2012; Best 2005; Majid et al. 2001), even in islets of mice lacking NKCC1 (Alshahrani and Di
Fulvio 2012), suggesting the presence of a BTD-sensitive mechanisms operating in the control of
insulin secretion. These mechanisms are probably represented by NKCC1 and NKCC2, as both
cotransporters are co-expressed in #-cells (Alshahrani et al. 2012). The role of NKCCs in insulin
secretion is highlighted by the widely held concept that BTD is a "diabetogenic" drug
contraindicated in those patients with underlying glucose intolerance (Furman 1981; Giugliano,
et al. 1980; Robinson, et al. 1981). Indeed, several studies have shown that acutely administered
BTD impairs the ability of pancreatic "-cells to release insulin by directly affecting the cells
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(Sandstrom 1988, 1990; Sandstrom and Sehlin 1987, 1988a, b, c). However, these studies were
neither confirmed nor followed up.
We now know that NKCCs and [Cl–]i are important components of the machinery
involved in the secretion of hormones including the following: thyroid hormone releasing factor
(Bacova, et al. 2006), thyroid stimulating hormone (Lim, et al. 1995), thyroid hormones
(Armstrong, et al. 1992a; Armstrong, et al. 1992b; Bourke, et al. 1995; Fanelli, et al. 1995; Yap,
et al. 1991; Yap, et al. 1994), vasopressin and oxytocin (Kim, et al. 2011), gonadotrophin
releasing hormone (Donoso, et al. 1994; Nakane and Oka 2010; Watanabe, et al. 2009), central
somatostatin (Gamse, et al. 1980; Llorens-cortes, et al. 1992; Rage, et al. 1992), prolactin
(Markoff, et al. 1982; Sartor, et al. 2004), glucagon-like peptide-1 (Gameiro, et al. 2005) and
parathyroid hormone (Rejnmark, et al. 2001). Nevertheless, the mechanisms involved in all these
cases are not fully understood.

1.11.

Regulation of NKCC1 function and expression
Theoretically, regulation of NKCC1 may occur at many steps, either at the

transcriptional, post-transcriptional, translational or post-translational levels. In fact most of our
knowledge regarding regulation of NKCC1 is at the functional level via post-translational
mechanisms, particularly phosphorylation of the plasma membrane inserted transporter (Kahle,
et al. 2010) (see next Section 1.12). There is also some indirect evidence suggesting that Nglycosylation, a co- and post-translation modification of many proteins is also involved in
NKCC1 plasma membrane trafficking and function. However, these latter regulatory
mechanisms have been inferred rather than demonstrated, based on experiments performed in
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over-expression systems using NKCC2 or NCC rather than NKCC1 (Benziane et al. 2007;
Hoover et al. 2003; Paredes, et al. 2006; Zaarour et al. 2011; Zaarour et al. 2009; Zaarour et al.
2012).
The long-term mechanisms involved in NKCC1 plasma membrane location or expression
are unknown. Clearly, elucidating the mechanisms whereby NKCC1 is expressed at the protein
level or reaches the plasma membrane where BTD can exert its inhibitory role is relevant when
these concepts are placed within the context that low doses of BTD are of potential clinical use
to treat several conditions not necessarily related with the diuretic action of the drug.

1.12.

Regulation of NKCC1 function: Phosphorylation
It has long been recognized that the function of NKCCs largely depends on the

phosphorylation state of the transporter. Indeed, phosphorylation plays a key regulatory role for
many members of the SLC12A family (Kahle, et al. 2005; Kahle et al. 2010; Moriguchi, et al.
2005; Pacheco-Alvarez and Gamba 2011; Richardson, et al. 2011; Rinehart, et al. 2005). NKCC1
function is acutely activated by phosphorylation in key N-terminal residues in response to
decreased [Cl–]i or cell shrinkage, the latter being of capital importance for the activation of
kinase(s) of the "with no lysine" (WNK) or Ste20-type kinase (SPAK) families (Kahle et al.
2010). Although many of the studies carried out to demonstrate the participation of key
phosphoresidues were performed in over- expression systems such as the Xenopus laevis oocyte,
it is accepted that WNKs influence [Cl–]i and cell volume by enhancing the activity of plasma
membrane inserted NKCC and inhibiting KCC either directly or indirectly through downstream
SPAK kinases.
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Besides the direct role that phosphorylation has on NKCC1 activity, it has been suggested
that similar phosphorylation cascades may promote membrane trafficking of NKCC1 in neurons
of the dorsal root ganglion (Galan and Cervero 2005). However, whether phosphorylation is
required for trafficking is still matter of debate as it was not possible to discern between
phosphorylation of the transporter and trafficking from trafficking of NKCC1 and
phosphorylation once trafficked.

1.13.

Regulation of NKCC1 by N-glycosylation
Protein glycosylation is a metabolic process highly conserved in evolution (Alberts, et al.

2008; Breitling and Aebi 2013; Freeze 2013). In eukaryotic cells, secreted and membrane bound
proteins are frequently co- and post-translationally modified in numerous ways in the
endoplasmic reticulum (ER) and Golgi apparatus. In the ER, proteins attain functional properties
as we may know them, other times these proteins are targeted to particular compartments either
to perform their function, to be degraded before or trafficked to Golgi compartments for further
processing or "maturation" (Figure 4).
Among the many known post-translational modifications different from phosphorylation,
the enzymatic attachment of an oligosaccharide to nascent proteins i.e., N-glycosylation and Oglycosylation play key roles in protein stability, folding, trafficking and function (Araki and
Nagata 2011; Breitling and Aebi 2013; Hebert and Molinari 2007; Kleizen and Braakman 2004;
Roth, et al. 2010). These two types of protein modification occur in asparagine (N) residues
within the context Asn-X-Ser/Thr (NXS/T, where X is any amino acid residue except proline) or
at the $OH group of Ser/Thr residues [(Alberts et al. 2008), Figure 5]. However, efficient N-
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Figure 4. The secretory pathway of the cells. Proteins whose fate is their secretion, the
plasma membrane or any other organelle within the cell are synthesized in the ribosomes
attached to the ER. Entry of proteins to the ER ensures co-translational modifications such
as leader peptide cleavage and N-glycosylation, a process that helps proteins attain their
native stable structure. This task is under the close scrutiny and surveilance of the ER
quality control system (QC). Proteins with stable folding and assembled are the ones with
more chances to transit to the cis-Golgi for further N-glycan modification, elaboration or
decoration and perhaps additional quality control checkpoints. Direccionality of vesicular
movement between compartments of protein cargoes within the ER are indicated as black
arrows. Red arrows indicate homeostatic mechanisms taking place during protein
biosynthesis. Misfolded, unstable or aggregated proteins are recognized by yet undefined
mechanisms, retained and eventually degraded via ER-associated degradation (ERAD) or
autophagy (blue arrows). Soluble unstable or misfolded proteins who escape this
retrotranslocation are transported to the ER-Golgi intermediate compartment (ERGIC) or
cis-Golgi to be retrotranslocated for degradation. A high load of protein synthesis usually
observed in over-expression experiments stresses the ER triggering the “unfolded protein
response” (UPR), which can selectively decrease entry of proteins into the ER, increase
folding capacity, degradation or even change the N-glycosylation state of substrates
[modified from Anelli and Sitia (2008)].
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Figure 5. Glycoproteins. The glycan nature of glycoproteins is usually classiffied based on
the chemical bonds linking the glycan and the protein. For instance, N-glycans are attached
to especific asparragine (N) residues in the protein’s skeleton whereas O-linked glycans use
the oxygen atom of the −OH group in serine (S) or threonine (T) residues. When comparing
all glycans, the chemical nature of O-glycans is the simplest one, usually containing few
sugars of different kinds. N-glycans, however, may become highly elaborated. N-glycans
are further classified according to the nature of the sugars linked to the two molecules of
N-acetyl glucosamine (GlcNAc) attached to N residues. Oligomannose or high-mannose
N-glycans are characterized by ~9 mannose residues whereas hybrid-type N-glycans
typically contain ~5 mannose residues, one of which is further branched with sugars of
variable nature and length. Complex N-glycans have fucose and sialic acid residues in the
sugar structures.
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glycan biosynthesis on a particular sequon of a polypeptide is under positive selection pressure.
This is due to the natural preference of the enzyme involved the first step of N-glycan
biosynthesis for NXT over the NXS sequons, a finding demonstrated in all species so far
examined (Zielinska, et al. 2012). In addition, it is important to keep in mind that the presence of
an N-glycosylation sequon, either NXT or NXS in a protein is not sufficient to define an Nglycosylation site (Aebi 2013; Lau, et al. 2007). Experimental demonstration is always needed.
Protein modification involving N-linked glycans is of specific interest because N-linked
glycosylation is essentially required for cellular viability and function of numerous proteins
(Kukuruzinska and Lennon 1998) and deficiency of one or several of the enzymes involved in
processing N-glycans are usually lethal (Freeze 2013; Freeze and Ng 2011). Characteristically,
N-glycan biosynthesis involves a multitude of enzymes and genes, which function in the
biosynthetic secretory pathway in a coordinated manner (see Section 1.15). Conceptually
speaking, it is important to mention that N-glycan biosynthesis is not a phenomenon dictated by
the protein template, as it is the case for DNA, RNA or actually protein biosynthesis. In fact, the
function of the secretory pathway depends on the transit of substrate proteins en route to their
final destination, which could be the plasma membrane or any other organelle, or even secretion
(Stanley 2011; Stanley, et al. 2009). In general, substrate proteins created and subtly modified in
the ER are then transported to the Golgi apparatus while undergoing further modifications and
elaboration by enzymes resident in these compartments (Aebi 2013; Breitling and Aebi 2013).
To which extent and what kind of modifications and glycan decorations a protein may undergo
depends on the availability of activated sugars in a given cell, the order or sequence in which the
protein substrate reaches glycosyl-transferases, glucosidases, mannosidases, galactosidases and
many other glycan processing enzymes residing in ER and Golgi as well as the molar amount of
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such proteins relative to enzymes. Therefore, not all proteins will encounter the same set of
enzymes, the same order or identical conditions to become N-glycans and therefore, the
molecular nature of N-glycans attached to proteins is not only highly variable, leading to the
generation of different N-glycans, but also not-quantitative and heavily dependent on the
biosynthetic rate of the protein substrate (Aebi 2013; Breitling and Aebi 2013).

1.14.

N-glycosylation and protein trafficking
N-glycosylation impacts the cellular trafficking of many proteins, including transporters.

For instance, N-glycosylation plays a role in insulin secretion by regulating the availability of
glucose transporter activity in the plasma membrane of the insulin secreting #-cell. Indeed,
mutation of N-glycosylation sites in the glucose transporter 4 (GLUT4) impairs the ability of the
transporter to traffic to the plasma membrane resulting in reduced glucose uptake (Haga, et al.
2011). In addition, comparable results have been reported for some subunits of the K+ channels
but not for all of them (Mant, et al. 2013), indicating that N-glycosylation may impact
differentially the ability of channels or even transporters to reach the plasma membrane.
Interestingly, non-glycosylatable mutants of the transporter SLC26A4 known as Pendrin, a Cl–-I–
/HCO3– exchanger, did not affect the ability of Pendrin to reach the membrane, although its
transport function was decreased (Azroyan, et al. 2011). In the case of the close relative of
NKCC1 i.e., NKCC2 site-directed mutagenesis involving N-glycosylation residues and over
expression experiments in Xenopus oocytes or mammalian cells draw the picture including Nglycosylation as an important determinant of NKCC expression and function in the plasma
membrane (Benziane et al. 2007; Hoover et al. 2003; Paredes et al. 2006; Zaarour et al. 2011;
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Zaarour et al. 2009; Zaarour et al. 2012). However, the role of N-glycosylation per se on the fate
of non-glycosylatable NKCC2 mutants cannot be distinguished from the potential effects that Nglycan maturation may have on protein trafficking, clearly because a non-N-glycosylatable
mutant cannot mature. It is evident that a protein that cannot be N-glycosylated cannot mature,
may not fold properly and may suffer degradation, therefore precluding delivery of the protein to
any cellular compartment. This fact coupled to the high levels of NKCC2 expression achieved in
transfection experiments makes difficult the interpretation of experiments aimed at relating Nglycosylation, non-glycosylatable mutants and trafficking. Hence, in order to study the potential
role of N-glycosylation in protein trafficking, plasma membrane insertion and function, it might
be more physiological to study the fate of endogenous proteins upon specific pharmacological
inhibition of enzymes involved in key steps of the N-glycan biosynthesis pathway.

1.15.

N-glycosylation steps
As briefly mentioned, newly synthesized proteins translocate into the ER and are rapidly

glycosylated in N residues within the sequon NXS/T (Aebi 2013; Alberts et al. 2008; Breitling
and Aebi 2013). This task is initiated with the transfer of an !-linked N-acetyl-glucosamine
(GlcNAc)-phosphate from a uridine-diphosphate (UDP)-GlcNAc to dolichol (Dol) phosphate
producing GlcNAc-PP-Dol, a step highly sensitive to the antibiotic tunicamycin (TUN) (Elbein
1984). Therefore, inhibiting N-glycosylation at this first step in N-glycan biosynthesis has a wide
variety of effects on protein fate, not only because the protein cannot mature, but also because
absence of N-glycosylation impairs protein transit, secretion, folding and stability resulting in
decreased total protein expression levels and therefore, absence or decreased delivery of proteins
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to any cellular compartments, a strikingly similar concept related to the use of nonglycosylatable mutants.
This first TUN-sensitive step in N-glycan biosynthesis facilitates protein interaction with
ER chaperones and ER resident enzymes such as calnexin (CNX) and calreticulin (CRT)
preventing protein aggregation, misfolding and degradation (Araki and Nagata 2011; Hebert and
Molinari 2007; Kleizen and Braakman 2004; Roth et al. 2010; Vagin, et al. 2009). Actually, ER
chaperones interact with newly synthesized N-glycans only if the sugar chains added in the first
step of N-glycosylation are trimmed by a group of ER-resident deoxynojirimycin-sensitive
glucosidases (Araki and Nagata 2011). An overview of these steps is schematized in Figure 6
[see (Stanley 2011) for an extensive review]. The removal of glucose residues in the nascent Nglycan chain promotes protein folding whereas inhibition of these enzymes, or their absence
results in increased expression of core N-glycosylated precursor proteins, increased time of
residence in the ER and therefore better chances for the immature protein to get degraded by the
ubiquitin-proteasome pathway after retro-translocation to the cytosol (Araki and Nagata 2011).
Binding of N-glycans to CNX and CRT facilitates protein folding and stable
conformation (Araki and Nagata 2011; Hebert and Molinari 2007; Roth et al. 2010). After
attainment of stable conformation through this quality control step, glucosidase II trims a single
glucose residue from the N-glycan chain increasing the relative content of mannose residues and
producing proteins with high-mannose content. During interaction of N-glycan with CNX/CRT,
some proteins may not stably fold, increasing the timing of their residence and increasing the
chances of UDP-glucose:glycoprotein-glucosyltransferase to re-glucosylate N-glycan chains
promoting an extra cycle of glycoprotein interaction with the CNX/CRT quality control
machinery in the lumen of the ER. This glucosyl-transferase activity functions as a sensor for
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al (2009)].
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poorly folded proteins whilst the de-glucosylation/re-glucosylation process continues until the
conformation of the protein substrate is stable enough to reach a critical level to continue the
journey to the Golgi (Stanley 2011).
On one hand, N-glycans failing to attain stable conformations after repeated cycles of
CNX/CRT interactions are usually retro-translocated from the ER to the cytoplasm where they
are degraded by the proteasome in a process known as ER-associated degradation (ERAD) (Roth
et al. 2010). On the other hand, those N-glycans passing the quality control accumulate in the ER
and become substrates of the kifunensine (KIF)-sensitive !-mannosidase I (Elbein, et al. 1991), a
step necessary prior to exporting proteins from the ER to the Golgi (Kukuruzinska and Lennon
1998). N-glycans trimmed of one or two mannose residues by the action of KIF-sensitive
enzymes are then ready to become substrates of cis-Golgi-resident enzymes involved in Nglycan processing (Figure 6) (Stanley 2011). It is in the cis-Golgi where N-glycan chains are
further modified to form N-glycans of hybrid, endoglycosidase H (EndoH)-sensitive nature to
culminate in N-glycans of complex, mature EndoH-resistant nature by the action of series of
medial- and trans-Golgi-resident glycosyl-transferases and glycosidases, including swainsonine
(SWN)-sensitive !-mannosidase II (Man2) involved in the last and first step of hybrid- and
complex-type N-glycan biosynthesis respectively (Elbein 1984; Elbein, et al. 1981; van den
Elsen, et al. 2001). In general, the consensus notion states that it is at this last stage of N-glycan
biosynthesis when N-glycoproteins are "mature" and ready to be transported to different cellular
compartments including plasma membrane. However, not all proteins require complex Nglycosylation to reach plasma membrane and protein "maturity" does not necessarily reflect the
N-glycan nature of the protein. High-mannose N-glycans in the cis-Golgi serve as substrates for
diversification, elaboration and decoration, and thus modifying the N-glycan content from high-

30

mannose to hybrid or complex glycan subtypes. When total N-glycans are estimated from
various cells and tissues, the majority of extracellular N-glycans are found to be of the complex
type. It is important to note that multiple N-glycosylation sites on the same protein may contain
different types of N-glycans and that sugar nucleotide metabolism efficiency, rates of transport in
ER and Golgi, localization of oligosacharyl-transferases are considered to determine the final
type of N-glycan nature (Stanley 2011).
In the specific case of NKCC1, we simply know that the transporter has two well
conserved N-glycosylation sites i.e., N456 and N466 within the predicted long extracellular loop
between the seventh and eighth transmembrane spanning segments (see Figure 3). Like other
proteins and due to the fact that NKCC1 is indeed N-glycosylated in vivo, it is predicted that
during core-N-glycosylation of NKCC1, glycan chains are linked to either one or both Nglycosylation sites in a TUN-sensitive manner. Subsequently, it is expected that core highmannose

N-glycosylated

NKCC1

undergoes

a

series

of

enzymatic

reactions

i.e.,

glucosylation/de-glucosylation, de-mannosylation in the ER and later in Golgi cisternae where
additional trimming and decoration of the N-glycan structure may occur conferring the protein
potential N-glycan complexity, stability and competence to reach the plasma membrane. Indeed,
the prevailing notion states that this complex N-glycosylated NKCC1 is the one present in the
plasma membrane, a location where NKCC1 can be functionally determined (Nezu et al. 2009).
However, we hypothesize that plasma membrane location of exogenously over-expressed
NKCC1 does not reflect with fidelity the natural locations of the endogenous transporter. In fact,
as it is the case of many proteins, a small proportion of total cellular NKCC1 may reach the
plasma membrane independently of the hybrid or complex nature of its N-glycan structure.
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1.16.

Cellular models to study N-glycosylation and trafficking of proteins
Among the many mammalian cell lines used to study the secretory pathway of proteins,

the kidney fibroblast-like COS7 cell line stands above other commonly used cells lines such as
CHO, HeLa, 3T3, HEK or Vero, not only because COS7 are exceptionally amenable for DNA
transfection or over-expression experiments or because they have been used extensively to study
the secretory mechanisms of many proteins and hormones (Asai, et al. 2003; Chanmee, et al.
2013; Duzhyy, et al. 2005; Inomoto, et al. 2007; Karaplis, et al. 1995; Kim, et al. 2008b; Lai and
Michelangeli 2012; Lucocq, et al. 2001; Oner, et al. 2013; Perone, et al. 1998; Shin, et al. 2011),
but also because of their unique morphological nature and high adherence to microscopy
coverslips. Indeed, COS7 cells are big, flat and transparent while exhibiting negligible autofluorescence and are usually attached to glass within minutes making them ideal for microscopy
studies. In fact, the ultrastructure of COS7 cells as well as their secretory pathway have been
extensively characterized during the years (de Jonge, et al. 2009; de Jonge, et al. 2010; Dunphy
and Rothman 1985; Emr, et al. 2009; Ge and Schekman 2013; Kim, et al. 2008a; LippincottSchwartz 1998, 2011; Peckys, et al. 2013; Peckys, et al. 2009; Pelham and Rothman 2000;
Rothman and Orci 1990; Rothman and Wieland 1996; Salama and Schekman 1995; Sengupta, et
al. 2013; Sengupta, et al. 2012; Yamamoto, et al. 1998). The work performed in these and other
cell lines of similar morphology mainly in the laboratories of Drs. Rothman, Schekman and
Südhof culminated in a detailed view of how the cell organizes its transport/secretory system an
effort that was recognized with the 2013 Nobel Prize award in Physiology/Medicine
(www.nobelprize.org/nobel_prizes/medicine/laureates/2013/press.html).
Based on the above mentioned considerations, the wealth of information relating the
secretory pathway of COS7 cells and the fact that the mechanisms involved in intracellular
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trafficking of endogenous NKCC1 are unknown, we decided to study the impact of Nglycosylation on the intracellular trafficking of NKCC1 endogenously expressed in COS7 cells.
The elucidation of the mechanisms involved in NKCC1 protein trafficking in COS7 cells, a cell
model wherein the secretory pathways is exceptionally well characterized will be of capital
importance to understand the long-term ability of cells to respond to a wide variety of signals
such as GABAergic signaling or glucose and nutrient availability. Further, understanding the
mechanisms involved in long-term plasma membrane insertion of NKCC1 in non-polarized cells
with defined regulated secretory pathway such as the insulin secreting "-cells may help develop
therapeutic strategies aimed at improving insulin secretion.

33

2. HYPOTHESIS AND SPECIFIC AIMS
2.1.

Hypothesis: N-Glycosylation regulates localization and trafficking of NKCC1

2.2.

Specific Aims: The objectives of this study are:
2.2.1.

To determine the molecular identity and N-glycosylation state of NKCC1
endogenously expressed in COS7 cells

2.2.2.

To determine plasma membrane location of NKCC1 and cell
compartmentalization in these cells

2.2.3.

To determine the impact of N-glycosylation and N-glycan maturation on plasma
membrane targeting of endogenous NKCC1
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3. MATERIALS & METHODS
3.1. Materials: Pfx thermostable DNA polymerase, RNase-OUT, SuperScript-III reverse
transcriptase and random hexamers were from Invitrogen (Carlsbad, CA); dNTPs were
from Affimetrix/USB (Cleveland, OH); custom DNA primers for PCR were from
Integrated DNA Technologies (Coralville, IA); the RNAeasy minikit for RNA purification
was from Qiagen (Valencia, CA). Pre-casted SDS-polyacrylamide gels, running buffer,
protein molecular weight markers, protease/phosphatase inhibitor cocktails and
SuperSignal West Pico Chemiluminiscence kits were form Pierce (Thermo Scientific,
Rockford, IL). Culture supplements and general chemicals were from Life Technologies
(Carlsbad, CA) and Sigma (Saint Louis, MO), respectively. Microscopy materials were
from Electron Microscopy Sciences (Hatfield, PA) and Vector Labs (Burlingame, CA).
Tissue culture media and serum was from Thermo Fisher Sci. (Pittsburg, PA). Inhibitors of
N-glycosylation were from Cayman Chemicals (Ann Arbor, MI) and MP Biomedicals,
LLC (Solon, OH). DNA ladders, Peptide N-glycosidase F (PNGaseF) and endoglycosidase
H (EndoH) were from New England Biolabs, Inc (Ipswich, MA).
3.2. Antibodies: The primary antibodies used in this work are summarized in Table II.
Conjugated secondary antibodies for immunofluorescence or Western blotting were from
Jackson Immunoresearch Laboratories, Inc. (West Grove, PA). Primary antibodies were
used at dilutions indicated in each respective section. Stocks of these antibodies were
immediately prepared upon arrival by adding an equal volume of glycerol molecular
biology grade (Affimetrix/USB, Cleveland, OH) to avoid freezing/thawing cycles while
storing. Aliquots of the stocks were prepared and stored at $80ºC. Working aliquots were
kept at $20ºC during use. Lyophilized secondary antibodies either for immunofluorescence
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Table II. Antibodies used
Antibody
NKCC1 (T4)
LAMP
β-actin
Tubulin
Rab11
Calreticulin
NKCC1 (ck)
α-Mannosidase II
GAPDH

Application
WB/IF
IF
WB
WB
IF
IF
WB/IF
IF
WB

Description
Mouse monoclonal
Mouse monoclonal
Mouse monoclonal
Mouse monoclonal
Rabbit polyclonal
Chicken polyclonal
Chicken polyclonal
Rabbit polyclonal
Rabbit polyclonal

Provider*
DSHB
DSHB
DSHB
DSHB
BDTL
TS
TS
LSBio
SCBT

*DSHB: Developmental Studies Hybridoma Bank (University of Iowa), BDTL: BD Transduction

Laboratories (San Jose, CA), TS: Thermo Scientific (Rockford, IL), LSBio: Life Span (Seattle, WA),
SCBT: Santa Cruz Biotechnology (San Jose, CA)
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experiments or Western blotting applications were dissolved in appropriate volume of
water upon arrival, then aliquoted or stored at $80ºC. Working aliquots of these antibodies
were kept at $20ºC after diluting with glycerol 1:1 (v/v). The final dilutions of these
antibodies used in immunofluorescence are indicated in their respective sections.
3.3. COS7 cells: The Cercopithecus aethiops kidney fibroblast-like cell line COS7 was
obtained from the American Type Culture Collection (ATCC, Manassas, VA). This cell
line derives from CV1 cells by transformation with an origin defective mutant of SV40
encoding for the T antigen, a protein required for exogenous expression of constructs under
the command of the cytomegalovirus promoter (Gluzman 1981). Due to the nature of our
experiments and our objectives we selected this cell line based on the rationale delineated
in Section 1.16.
3.4. Cell culture: Adherent COS7 cells were cultured essentially as described (Di Fulvio, et al.
2008; Di Fulvio, et al. 2007a; Di Fulvio, et al. 2007b; Di Fulvio, et al. 2006). Briefly, cells
were grown in Dulbecco's modified Eagle's medium (DMEM) containing 4.5g/L glucose, 4
mM L-glutamine, 1mM sodium pyruvate, 10% (v/v) fetal bovine serum (FBS), 100 IU/ml
penicillin and 100µg/ml streptomycin or 1X antimycotic-antibiotic mix (Stock 100X). Cells
were grown in 5% CO2 at 37ºC and medium changed every 2 days until desired confluence
was reached. Culture of cells was achieved in treated flasks of 75 cm2 (T75) and used no
more than 30 passages. Cells were propagated by enzymatic digestion of the extracellular
matrix by using 3-4 ml 0.25% (w/v) trypsin supplemented with 0.53 mM EDTA 5 min at
room temperature. Cell detachment was followed under an inverted microscope until all
cells were suffused. Trypsin-mediated digestion was stopped by addition of complete FBS-
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containing culture medium. The total number of detached cells was then used to seed either
four T75 flasks or the appropriate number of 6 or 12-well plates.
3.5. RNA extraction: Total RNA was obtained using the RNAeasy kit following the
manufacturer's instructions and some modifications. Briefly, ~90% confluent COS7 cells
growing in T75 flasks were washed with ice-cold phosphate-saline (PBS) buffer, pH 7.4,
three times and collected by adding 1.2 ml of a highly chaotropic RNA-denaturing solution
containing 4M guanidinium isothiocyanate and 12 !l of "-mercaptoethanol (lysis buffer).
The cell lysate was passed through fine needles attached to 1 ml sterile glass syringes until
the solution reached appropriate viscosity in order to precipitate total RNA. This was done
adding cold 75% ethanol to the lysates followed by vigorous shaking. Precipitated RNA
was attached to silica filters placed in mini-columns, washed with ethanol solutions and
eluted with water (40 to 50 !l). The concentration of total RNA in the eluate typically
ranged from 1 to 3 !g/!l.
3.6. Reverse transcription coupled to the polymerase chain reaction (RT-PCR): First-strand
cDNA synthesis was started using ~1 !g of total RNA, 250 ng of random hexamers, 500
!M dNTPs, 10 mM DTT, 40 units RNase OUT and 200 units of SuperScript III reverse
transcriptase. The reaction mixtures were incubated at 50ºC for 50 min to allow cDNA
synthesis to occur. PCR was performed using aliquots of synthesized cDNA (0.5-1!l) as
we have recently described in detail elsewhere (Alshahrani et al. 2012). Screening of
NKCC1 transcripts present in the cDNA mixture was performed using the following sets of
PCR primers designed using human SLC12A2 mRNA sequences of reference
(NM_001046) as template. Their names and sequences (from 5' to 3') are: NKCC1516a/468b sense: ATG GAG TAG TGG TTA TTC GCC TAA AAG AAG, NKCC1-
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516a/468b antisense: TGA TAT CAG AAA AGT CTA TCC GGA ACT TGC; NKCC1608a/560b sense: ACA TAC AAT ATG GAG TAG TGG TTA TTC GCC, and NKCC1608a/560b antisense: ATG AAG TCT GTA TGG CTC AAT GAT TTC CTC. Positive
controls for RT-PCR reactions were performed using glyceraldehyde phosphate
dehydrogenase (GAPDH, NM_002046) primers: GAPDH-555 sense: GTG AAG GTC
GGA GTC AAC GGA TTT, GAPDH-555 antisense: CAC AGT CTT CTG GGT GGC
AGT GAT. Negative controls consisted in reactions containing GAPDF-555 primer set but
no total RNA. Primer design and in silico analysis of sequences obtained were performed
by using the Primer3 algorithm part of Geneious R6 suite (Biomatters, Auckland, New
Zealand).
3.7. Western Blotting: Western blot analysis was performed using protein lysates obtained
from COS7 cells and was based on standard protocols (Kurien, et al. 2009). Briefly, ~90%
confluent cells in T75 flasks were placed on ice and washed twice with 1X PBS and lysates
were obtained by scratching the cells using a lysis buffer of the following composition: 50
mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 0.1% (v/v) "mercaptoethanol, 1% (v/v) Triton X100 plus 1 mM phenylmethylsulfonyl fluoride (PMSF),
1mM) and additional protease/phosphatase inhibitors added as cocktails composed of 4-(2Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), aprotinin, leupeptin,
pepstatin,

bestatin,

1-[N-[(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl]-amino]-4-

guanidinobutane] (E-64), 50 mM NaF, 500 !M Na3VO4, 5 mM Na2P2O7 and 10 mM "glycerophosphate. The total protein content of cell lysates was determined using the
Bradford's reagent method (BioRad, Hercules, CA). Standard curves were prepared using
purified BSA as a standard. Twenty five-fifty µg of total protein in a final volume of 20!l
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were mixed with 20 µl of loading buffer containing 8% (w/v) sodium dodecyl sulfate
(SDS), 125 mM Tris-HCl pH-6.8, 20% (v/v) glycerol, 0.02% (w/v) bromophenol blue and
100 mM dithiothreitol, and boiled for 5 minutes before loading the samples on the gels.
Samples were loaded onto pre-casted Tris-HEPES 4-20% SDS-PAGE protein gels
(Thermo Scientific-Pierce, Rockford, IL) and separated by electrophoresis for ~1 hour at
100V until bromophenol ran to the end. Electrophoresed proteins were then electrotransferred onto PVDF membrane (Millipore, MA) at 4ºC for ~2 hours at 72V. Membranes
were then air dried and blocked with 5% BSA in 50 mM Tris-HCl, 150 mM NaCl
supplemented with 0.05% (v/v) Tween 20 (TBST) at room temperature (RT). After
blocking, membranes were cut and blotted at 4ºC using primary antibodies raised in
chicken and directed against human NKCC1 (1:1000), "-actin (1:3000), GAPDH (1:1000)
or tubulin (1:500) in 5% BSA-TBST. "-actin, tubulin or GAPDH expression levels were
used as internal loading controls. After blotting, membranes were washed twice with TBST
for 5 minutes at RT using gentle rocking. To develop the antigen-antibody reactions,
membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary
antibodies directed against chicken or rabbit immunoglobulins (dilution 1:2000 in TBST) at
RT for ~1 hour. Membranes were then washed three times with TBST 5 min and developed
by using chemiluminescence. Blots were visualized by exposing the membranes for 15
seconds in a BioRad image analyzer (Chemi-Doc MP Imaging system, Hercules, CA). The
relative amount of immunoreactive NKCC1 present in blots was determined by
normalizing the densitometric signal to that of "-actin or GAPDH. Densitometric analysis
was performed on digitalized blot images by using Image Lab Quantitative software
(BioRad, Hercules, California) or ImageJ (NIH).
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3.8. Protein determination: Protein was estimated in control and treated samples using two
different methods. Firstly, Bradford reagent was used to measure the total protein using 0-7
µg/µl BSA as standard. Bradford reagent was used in a 1:5 ratio in water and protein
absorption was determined at 595 nm. Total protein in samples was calculated using
standard curves having R2 values of ~0.99. Bradford protein estimation was followed for
immunoblotting procedures. Secondly, the bicinchoninic acid (BCA) assay (Thermo
Scientific, Rockford, IL) was employed to analyze total protein concentrations for Rb+ flux
studies. Reactive BCA was prepared following manufacturer's instructions and protein was
measured utilizing 0-5 µg/µl BSA as standards. Protein absorption was determined at 560
nm and the total protein content was calculated by using standard curves.
3.9. De-glycosylation: To determine the N-glycan nature of NKCC1 expressed in COS7 cells,
protein extracts were subjected to enzymatic de-glycosylation using two enzymes: EndoH
and PNGaseF. As briefly mentioned in Sections 1.15, EndoH and PNGaseF cleave highmannose/hybrid and complex-type N-glycans, respectively. A conceptual diagram of these
reactions is shown in Figure 7.
3.9.1. PNGaseF treatment: To release and characterize N-linked glycans attached to
NKCC1, 25 µg of cell lysates were subjected to enzymatic de-glycosylation with
PNGaseF, a glycosidase that cleaves all N-linked glycans irrespective of their nature
i.e., hybrid- or complex-type. Samples were first denatured by boiling in the
presence of glycoprotein denaturing buffer containing 5% SDS and 400 mM DTT
for 10 min. Digestion was initiated by adding 50 U of PNGase F (50,000 U/ml), 2 µl
of reaction buffer (500 mM NaH2PO4) and 1µl of Nonidet P-40 at 37ºC for 1 hour.
Successful de-glycosylation of NKCC1 was confirmed by SDS-PAGE coupled to
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Figure 7. Enzymatic identification of glycoproteins. The N-glycan nature of glycoproteins
either, high-mannose or hybryd-type determines sensitivity to the enzyme
endo-β-N-acetylglucosaminidase H, also known as endoglycosidase H (EndoH). The action
of EndoH on these N-glycans leaves the proximal N-acetylglucosamine residue attached to
N residues. If this proximal N-acetylglucosamine residue is fucosylated in the
medial/trans-Golgi, the N-glycan becomes resistant to EndoH activity and the glycoprotein
is said to be “mature” enough to be considered complex N-glycosyated. High-mannose,
hybrid- or complex-type N-glycans are sensitive to peptide-N4-(N-acetyl-β-glucosaminyl)
asparagine amidase F (PNGaseF). With few exeptions, PNGaseF eliminates any N-linked
glycan structure attached to any peptide leaving behind aspartic (D) residues.
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immunoblotting as described above (Section 3.7).
3.9.2. EndoH treatment: Digestion of hybrid and high mannose N-glycans present in
NKCC1 were carried out by utilizing EndoH, an enzyme that cannot cleave
complex-type N-glycans, only hybrid-type or high-mannose types. Briefly, samples
containing 25 µg of total protein were incubated in glycoprotein denaturing buffer
containing 5% SDS and 400 mM DTT and boiled for 10 minutes in a water bath.
Denatured proteins were de-glycosylated by adding 50 U EndoH (50,000 U/ml) in
reaction buffer containing 500 mM sodium citrate at 37ºC for 1 hour. Digested
proteins were detected by following the immunoblotting procedures explained above
(see Section 3.7).
3.10. Plasma membrane biotinylation: The extracellular surface of growing COS7 cells was
biotinylated following published protocols (Elia 2012) with the modifications of Ortiz
(Ortiz 2006) and Nezu et al. (Nezu et al. 2009), and further adapted to our cell model.
Briefly, sub-confluent COS7 cells were incubated under control conditions or with nontoxic concentrations of N-glycosylation inhibitors i.e., TUN, KIF and SWN in DMEM
without FBS for 16 hours at 37ºC. Cells were then washed twice in ice cold PBS and
collected by scraping cells off the wells. The cells were collected and then pelleted at
2500xg 5 min. Supernatants were discarded and fresh ice cold PBS was added to the cells,
which were biotinylated by adding fresh 1 mM Sulfo-NHS (N-hydroxysuccinimido)-biotin
and incubating at 4ºC for 1 hour with gentle rocking. Then, biotinylated cells were
collected by centrifugation at 2500xg for 4 minutes, washed three times with ice-cold PBS
and lysed using complete lysis buffer (prepared as mentioned above, see Section 3.7)
containing protease/phosphatase inhibitors and PMSF for 15 min at 4ºC. Total biotinylated
!
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proteins were quantified using BSA as a standard and Bradford's method as indicated in
Section 3.8. To separate biotinylated membranes from the lysate mixture, 50 !g of protein
samples were incubated with 150 !l streptavidin-conjugated agarose beads (50% slurry
plus 0.02% NaN3) overnight at 4ºC with gentle rocking. Beads were then centrifuged at
15,000xg 5 minutes at 4ºC, washed three times with lysis buffer, three times with high salt
buffer (1M NaCl) and twice with no-salt buffer (PBS). Beads were then resuspended in
SDS-containing loading buffer, denatured for 5 min at 100ºC and subjected to SDS-PAGE
to follow the immunoblotting procedures described in Section 3.7. As control of the
purified membrane fraction, we used GAPDH instead of "-actin since the former is usually
not found in purified plasma membranes (Soundararajan, et al. 2009) whereas the latter
may locate near or at the plasma membrane (Hoock, et al. 1991).
3.11. Immunofluorescence: COS7 cells were grown on glass coverslips (Fisher Scientific.
#NC9130114) placed on 6-well plates following detailed procedures (Di Fulvio et al.
2007a). Briefly, cells were cultured in DMEM until ~60-70% confluence was reached to
ensure good imaging capabilities. Cells were washed twice in 1X PBS and fixed with
absolute methanol at $20ºC for 10 min. Cells were permeabilized using 4% pformaldehyde containing 0.25% (v/v) Triton X-100 at 4ºC for 15 min. After washing twice
with PBS, fixed and permeabilized COS7 cells were blocked against non-specific staining
by incubating them in 3% goat serum for 1 hour at 4ºC. Cells were then carefully washed
three times with PBS and incubated with primary antibodies against NKCC1 (T4, 1:1000)
alone or in combination with organelle markers: CRT (1:500), LAMP (1:1000), Rab11
(1:500) and !-mannosidase II (1:500) in 3% goat serum at 4ºC overnight. Next day,
immunolabeled cells were carefully washed off the primary antibodies four times with ice-

44

cold PBS and immediately incubated with fluorescently labeled-secondary antibodies
(Cy3- or FITC-conjugated) diluted in PBS (1:2000) for 2 hours at 4ºC. Cells were washed
four times with PBS and air-dried before placing the coverslips up-side down on
microscopic slides (24x50mm). To visualize cells, they were mounted using Vectashield
mounting medium containing 4'-6-diamidino-2-phenylindole (DAPI) to counterstain cell's
nuclei. Slides were then visualized in an Olympus Epi-Fluorescence microscope with RT
color camera using 60X oil objective and FITC/CY3/DAPI fluorescence filters.
Photomicrographs were obtained using Diagnostics Instrument Spot 6 digital camera and
MetaVue software (Microscopy Facility in BSoM).
3.12. Co-immunolocalization analysis: The analysis was based on the relative semi-quantitation
of overlapping pixels observed in high-resolution digital images (>300 dots per inch) taken
using different filters/channels and superimposed (overlays).

This estimation was

performed in silico and expressed as % overlap. We considered co-localization when pixels
of different channels shared the same bit area. All pixels were analyzed based on their
intensity as established in the algorithms used by the software suite Metamorph (Molecular
devices, Sunnyvale, CA) with minimal user interference. In general, selected areas of the
cells were measured for specific florescence signal under control and treated conditions and
the data obtained was plotted using Graphpad Prism 5 (San Diego, California).
3.13. Bumetanide-dependent Rb+ fluxes: Flux assays were performed in collaboration with Drs.
Adragna and Lauf following established methodologies (Adragna, et al. 2002) and adapted
to our cells. Briefly, COS7 cells were seeded onto 12-well plastic plates and grown until
~70-80% confluence. Cells were then incubated in the absence of FBS under control
conditions. Then, cells were washed three times in ice-cold isotonic (300 mOsmol/kg)
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balanced salt solution of Hank (BSS) containing 20 mM HEPES-Tris, 5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 10 mM glucose and 10 mM NaCl pH 7.4 and then cells were preequilibrated for 10 min at 37ºC in isotonic BSS supplemented with 0.1% (w/v) BSA (BSSBSA) and containing either 100 !M ouabain, an inhibitor of the Na+/K+-ATPase (EMD
Millipore) ± 10 !M bumetanide (BTD), an inhibitor of NKCCs. After pre-incubation,
medium was aspirated and cells incubated in isotonic BSS-BSA containing 10 mM RbCl (a
K+ congener) 10 minutes at 37ºC. After this incubation time, Rb+ influx was terminated by
washing the cells 5 times with isotonic solution of the following composition: 10 mM
MOPS-Tris-HCl and 10 mM MgCl2 at RT. The ionic content of cells was released by
adding 1 ml per well of 4 mM CsCl in 5% HClO4 acid solution and incubating the cells at
RT for 15 min. After neutralization (addition of 1 ml 1 M NaOH/well) an aliquot of 1000
!l was taken for protein determination using the BCA assay. Cellular Rb+ content was then
measured

by

atomic

emission

spectrometry

(Perkin-Elmer

5000

atomic

spectrophotometer). Rb+ uptake was calculated as nmoles of Rb+ per mg of total protein.
3.14. Statistical analysis: Analysis of multiple group differences was performed using one-way
analysis of variance (ANOVA) followed by Student-Newman-Keuls’ test. A p value less
than 0.05, was used as the criterion of statistical significance.
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4. RESULTS
4.1.

COS7 cells express NKCC1a at the mRNA level
It has been suggested that exon 21 in NKCC1a plays an important role in plasma

membrane targeting (Carmosino, et al. 2008). To confirm expression of exon 21 [48 base pairs
(bp)] in our cell model the presence of NKCC1a and NKCC1b transcripts was determined in
COS7 cells using RT-PCR following a similar strategy originally developed by Mao et al. (Mao
et al. 2012). To identify NKCC1 mRNAs we used two sets of primers encompassing the junction
between exons 20, 21 and 22. These primer sets i.e., NKCC1-608a/560b and -516a/468b are
predicted to co-amplify NKCC1a mRNAs as bands of 608 and 516 bp, respectively as well as
NKCC1b as 48 bp shorter i.e., 560 and 468 bp, respectively. A representation of these primers
relative to the relevant region of NKCC1 transcripts is shown in Figures 8A and 8B. The RTPCR results are shown in Figure 8C, where NKCC1 transcripts bands of 608 and 516 bp are
detected in COS7 cells whereas bands of 560 and 468 bp were not co-amplified. These results
indicate that NKCC1a mRNAs are expressed in these cells and that NKCC1b mRNAs are not.
Although these results suggest that the lack of detection of NKCC1b transcripts is not due to
primer design, we confirmed this possibility by using human brain cDNAs as source of NKCC1a
and NKCC1b transcripts. As shown in Figure 8D, NKCC1a and NKCC1b mRNAs are codetected as bands of predicted sizes, confirming undetectable NKCC1b mRNAs in COS7 cells.

4.2.

COS7 cells express NKCC1a at the protein level
To confirm NKCC1a expression at the protein level in our cell model, we performed
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Figure 8. NKCC1a transcripts are expressed in COS7 cells. A. Representation of the last
nine exons (filled boxes) of the human SLC12A2 gene. Alternative spliced exon 21 involved
in NKCC1a (NM_001046) and NKCC1b (NM_001256461) is shown as a red box. Introns
are represented with V-shaped lines. White boxes represent 3'-UTRs. B. Regions involved
in PCR amplification are shown as black arrows containing the names of primer sets used.
C-D. Shown are representative 2% agarose gels where bands of predicted sizes for
NKCC1a are detected in COS7 cells (C, 608 bp and 516 bp). In human brain, bands of
predicted sizes for NKCC1a and NKCC1b are co-amplified (D, 608 bp + 560 bp and 516
bp + 468 bp). As positive control, RT-PCR reactions amplified GAPDH (555 bp). As
negative control, RT-PCR reactions were performed using water instead of total RNA and
GAPDH-555 primer sets.
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immunoblotting experiments using two different antibodies directed against NKCC1: a
thoroughly characterized and widely used (Alvarez-Leefmans 2009) mouse monoclonal antibody
named T4, and a commercial polyclonal antibody raised in chicken (ckNKCC1) and directed
against a synthetic peptide of undisclosed identity corresponding to human NKCC1. As shown in
Figure 9A both antibodies detect the immunolocalization of NKCC1a in COS7 cells as two
major bands, one of ~135 kDa and another of ~170 kDa, allegedly corresponding to the
immature core/high-mannose and hybrid/complex N-glycosylated transporter, respectively
(Alvarez-Leefmans et al. 2001; Marty et al. 2002; Munoz et al. 2007; Payne and Forbush 1995).
T4 antibodies cross-react with NKCC2 (Alvarez-Leefmans 2009), at least when the latter
is expressed at very high levels, either forcedly in X. laevis or endogenously in kidney.
Furthermore, very low levels of NKCC2 exist in many extra-renal tissues and cells (Akiyama, et
al. 2010; Akiyama, et al. 2007; Alshahrani et al. 2012; Bensellam, et al. 2009; Corless, et al.
2006; Gavrikov, et al. 2006; Ghanaat-Pour and Sjoholm 2009; Kakigi, et al. 2009; Nickell, et al.
2007; Nishimura, et al. 2009; Xue, et al. 2009; Zhu, et al. 2011), including COS7 cells
(unpublished results). Therefore, we tested the specificity of ckNKCC1 antibodies in our cell
model. To this end, the immunolocalization of NKCC1 was first determined in protein extracts
from mouse liver, an abundant source of NKCC1 (Payne et al. 1995; Schliess, et al. 2002) and
the results compared to those obtained in tissues from mice lacking the transporter (NKCC1KO)
[Kindly provided by Dr. Alvarez Leefmans] (Flagella et al. 1999) and from kidney, the most
abundant source of NKCC2 in mammals (Di Fulvio and Alvarez-Leefmans 2009). As shown in
Figure 9B, NKCC1 expression is detected in a similar pattern as that observed for COS7 cells
(Figure 9A). However, ckNKCC1 antibodies failed to detect NKCC1 in liver from NKCC1KO
mice or NKCC2 from mice kidneys suggesting that, under our experimental conditions, these
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Figure 9. NKCC1a protein expression in COS7 cells. A. Shown is a representative
immunoblot of protein extracts obtained from COS7 cells cultured under basal conditions
and developed by using two different antibodies directed against NKCC1: T4 and
ckNKCC1. As loading controls, the immunoblots were probed in parallel using monoclonal
antibodies directed against β-actin (experiments performed by Romario Andrade). B.
Validation of ckNKCC1 antibodies. Protein extracts from liver were obtained from normal
or genetically enginnered mice lacking NKCC1 (NKCC1WT and NKCC1KO, respectively).
C-D. Expression of NKCC1 proteins at the cellular level. Shown are representative
immunofluorescence images of COS7 cells growing in glass coverslips under basal
conditions. NKCC1a expressed in COS7 cells was immunolabeled with T4 (C) or
ckNKCC1 (D). Bar represents 10 μm.
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antibodies detect NKCC1 and not other protein(s), including NKCC2. To further corroborate
expression of NKCC1 and to have insights into the potential cellular localization of the
transporter in our cell model, immunofluorescence experiments were performed in COS7 cells
using both T4 and ckNKCC1 primary antibodies. As shown in Figures 9C and 9D, a similar
pattern of immunoreactive NKCC1 in COS7 cells is detected by T4 and ckNKCC1 antibodies,
further validating the use of these antibodies to study expression pattern and localization of
NKCC1.

4.3.

A small proportion of endogenous NKCC1a is complex N-glycosylated
The results presented in Figures 9A and 9B suggest that NKCC1a is expressed in COS7

cells and tissues as an N-glycosylated protein, in agreement with published results (see Sections
1.4, 1.13-14 and references therein). To further corroborate the concept that NKCC1a is Nglycosylated in our cell model, enzymatic de-glycosylation coupled to Western blotting was used
to determine the basal N-glycosylation state and N-glycan nature of the endogenous transporter
in COS7 cells. To this end, protein lysates were treated with PNGaseF or EndoH, enzymes that
cleave all N-linked glycans and high-mannose/hybrid-type, respectively (see Fig. 7) and the
reaction products immediately subjected to Western blotting to detect shifts in the putative
complex-type N-glycosylated broad band of ~170 kDa towards one of ~130 kDa. As observed in
Figure 10A, treatment of protein samples with PNGaseF resulted in a significant, nearly
complete elimination of the ~170 kDa bands and a parallel ~2-fold increase in core NKCC1
levels (bands of ~130 kDa). These results suggest that at least half of total endogenous NKCC1
expressed in COS7 cells is of the hybrid/complex N-glycosylated type. Further, as shown in
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Figure 10. N-glycosylation state and nature of endogenous NKCC1a expressed in
COS7 cells. A-B. Representative immunoblots of protein extracts obtained from COS7
cells grown under basal conditions before (Control) and after treatment with PNGaseF (A)
or EndoH (B). As loading control, immunoblots were probed with antibodies against
β-actin. C. Densitometric analysis of immunoblots of proteins treated with PNGaseF of
EndoH. Shown are the densitometric levels before (Control) and after de-glycosylation
treatment of the two main immunobands of NKCC1a: ~170 kDa (red bars) and ~130 kDa
(green bars). Data are expressed as means ± SEM (n=5). D. Pie-chart representing the
relative contribution of core/high-mannose, hybrid- and complex-type N-glycans to the
total amount of endogenous NKCC1a in COS7 cells. Results are calculated based on the
percent densitometric increase in the bands of ~130 kDa post-enzymatic treatment e.g., if %
densitometric increase in ~130 kDa band post-PNGaseF treatment is 100% (C) then, 50%
of NKCC1a is hybrid + complex N-glycosylated. Similarly, if % densitometric increase in
~130 kDa bands post-EndoH treatment is ~50% (C) then, ~25% of NKCC1a is hybrid-type
N-glycosylated. Therefore, ~25% of total NKCC1a expressed in COS7 cells is complex
N-glycosylated.
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Figure 10B treatment of COS7 cells protein extracts with EndoH, which removes only Nglycans of the high-mannose/hybrid type, resulted in ~50% decrease of the 170 kDa bands of
NKCC1 indicating that of the total N-glycan composition of NKCC1a i.e., high-mannose/hybrid
and complex, half of it is hybrid-type. To visualize these changes in the NKCC1a bands of ~130
and ~170 kDa, immunoblots were densitometrically analyzed and plotted as percentage change
relative to control, untreated samples. The results are shown in Figure 10C and 10D. Taken
together, these results suggest that an estimated ~25% of total endogenous NKCC1a is complex
N-glycosylated in COS7 cells.

4.4.

Plasma membrane location of NKCC1a does not depend on the N-glycan nature of the
transporter
Although the role of N-glycosylation on NKCC1 plasma membrane targeting has not

been addressed so far, it is widely accepted that most of NKCCs are complex N-glycosylated and
that N-glycosylation of NKCCs plays a key role in plasma membrane targeting (Benziane et al.
2007; Zaarour et al. 2011; Zaarour et al. 2009; Zaarour et al. 2012). These observations together
with the results presented in Figure 10 predict that at least 25% of total endogenous NKCC1
may locate in the plasma membrane. To corroborate this prediction, total protein extracts and
biotinylated plasma membranes of COS7 cells were subjected to Western blotting to determine
the immunolocalization of NKCC1 in the plasma membrane fraction. The results are shown in
the immunoblots of Figure 11A. Unexpectedly and contrary to the general consensus, both
NKCC1a bands of ~130 and ~170 kDa were detected in the biotinylated plasma membrane
fraction indicating that "immature" core and complex/hybrid N-glycosylated NKCC1a are able
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to reach this cell location. To estimate the relative amount of NKCC1a either core or
hybrid/complex N-glycosylated (130 and 170 kDa, respectively) in the plasma membrane, we
performed densitometric analysis of immunoblots loaded with equal amounts of protein. As
shown in Figures 11B and 11C, approximately ~10% of total endogenous NKCC1a reaches the
biotinylated plasma membrane fraction, most of which corresponds to the core/high-mannose
“immature” N-glycan type fraction of the transporter. To visually estimate location near or at
plasma membrane, endogenous NKCC1a was directly immunolabeled in COS7 cells growing
under normal conditions. As shown in Figure 11D, most of endogenous immunoreactive
NKCC1a appears in intracellular compartments of COS7 cells, in small vesicles throughout the
cytoplasm and minimally at or near the plasma membrane (arrowheads, Fig. 11D).
It has been shown that non-glycosylatable mutants of NKCC2 do not efficiently reach the
plasma membrane and whatever reaches the membrane is hypo- or non-functional, at least when
expression of mutants is forced in oocytes (Paredes et al. 2006) or mammalian cells (Benziane et
al. 2007; Zaarour et al. 2011; Zaarour et al. 2009; Zaarour et al. 2012). To verify that plasma
membrane targeted NKCC1a either core/high-mannose or hybrid/complex N-glycosylated is
functional, we assessed the total NKCC transport activity in COS7 cells as BTD-dependent Rb+
uptake under basal steady state conditions. As shown in Figure 11E, COS7 cells express robust
total Rb+ uptake of which approximately half corresponded to BTD-sensitive Rb+ transport
(filled circles, Fig. 11E), suggesting that plasma membrane targeted NKCC1 is functionally
active in these cells. Therefore, when taken together with the data shown in Figures 10 and 11,
these results suggest that a minimal proportion of total endogenous NKCC1a, either
hybrid/complex or core/high-mannose N-glycosylated is functionally located in the plasma
membrane of COS7 cells and that most of the plasma membrane located NKCC1 is of the high-
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Figure 11. NKCC1a plasma membrane localization. A. Representative NKCC1a immunoblot of
equal amounts of total protein extracts and plasma membrane biotinylated fractions obtained from
COS7 cells growing under normal conditions and using ckNKCC1 antibodies. Shown are bands of
expected sizes of NKCC1a i.e., ~170 kDa and ~130 kDa in total cellular extracts and in biotinylated
plasma membrane fractions. Protein expression of cytosolic GAPDH was used as a loading control for
total protein lysates and to assess the purity of the plasma membrane fractions. B. Densitometric
analysis of immunoblots showing estimated levels of the main immunobands of NKCC1a:
core/high-mannose ~130 kDa (yellow bars) and complex/hybrid ~170 kDa (blue bars) in total lysates
or biotinylated plasma membrane fractions. Data is expressed as the mean ± SEM (n=3). C. Relative
contribution of total NKCC1a to the plasma membrane compartments. D. Immunofluorescence
analysis of fixed COS7 cells to examine the intracellular distribution of NKCC1a. As it is seen,
endogenous NKCC1a locates mainly in intracellular compartments and minimally at the edges of the
cell (arrowheads), suggestive of a location at or close to the plasma membrane. E. Shown is a
representative functional experiment performed in the laboratory of Drs. Norma Adragna and Peter
Lauf. The functional presence of NKCC1a in COS7 cells was determined as BTD-sensitive Rb+
uptake as a function of the incubation time. Data is expressed as mmol of Rb+ uptaken per mg of
protein. Each point represents the mean ± SEM (n=3).
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mannose N-glycosylated type.

4.5.

Endogenous NKCC1a locates in the ER and endosomal compartments
To determine the immunolocalization pattern of NKCC1a in COS7 cells we used

immunofluorescence microscopy coupled to antibodies directed against CRT, an ER-resident
lectin chaperone involved in protein-quality control (see Fig. 6) and widely used as an
established marker of the ER (Kleizen and Braakman 2004). As shown in Figures 12A-C,
immunoreactive endogenous NKCC1a locates in CRT-positive compartments suggesting that the
transporter locates in the ER. To further estimate the degree of NKCC1a/CRT co-localization,
we quantified the spatial overlap between NKCC1 (red) and CRT (green) signals in
immunofluorescence images using Metamorph software. As shown in Figure 12D, ~50% of the
total NKCC1a-related immunofluorescence signal overlaps with that of CRT, a proportion in
close agreement with the total amount of EndoH-sensitive NKCC1a signal obtained in
immunoblots (see Figs. 10B-C) and with the co-localization information visualized as heat-maps
obtained using a different algorithm i.e., the NIH ImageJ software suite. Clearly, NKCC1a also
locates in CRT-negative compartments. To identify these additional intracellular compartments,
endogenous NKCC1a was co-immunolabeled with Rab11, a small GTPase considered a steady
state marker of trans-Golgi network, secretory granules, constitutive exocytic vesicles and
recycling/sorting endosomes (Ren, et al. 1998; Urbe, et al. 1993). As shown in Figure 13, most
of endogenous NKCC1a locates in Rab11-positive compartments consistent with the notion that
NKCC1 is mostly confined to the intracellular space and further suggesting that NKCC1a may
constitutively traffic between all Rab11-positive compartments including recycling endosomes,
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Figure 12. Endogenous NKCC1a protein localization in the ER of COS7 cells. A-B.
Shown are representative images of COS7 cells where the immunological precense of
steady state NKCC1a (A) or calreticulin (CRT, B) were detected by using primary
antibodies against these proteins and developed using secondary antibodies fluorescently
labeled with Cy3 (NKCC1, red) and FITC (CRT, green). C. A+B pictures superimposed to
obtain an overlayed image where colocalization could be estimated as yellow pixels (red +
green = yellow). The scale bar shown in the inferior right corner of C represents 10 µm. D.
In silico semiquantitation of red (NKCC1), green (CRT) and yellow (NKCC1+CRT) pixles
using Metamorph software suite. Shown are the results obtained from 10 cells and
represented as mean fluorescence intensity in arbitrary units ± SEM. E. Colocalization
heat-map of the squared cell in C computed by using NIH ImageJ software.

57

B

6
4
2
0

Rab11
C

E
1

NKC
C1
Rab
11
NKC
C1+
Rab
11

NKCC1

D 8
Fluorescence initensity (AU)

A

NKCC1+Rab11

0
Overlay

-1

Figure 13. Endogenous NKCC1a protein localization in intracellular Rab11-positive
compartments in COS7 cells. A-B. Shown are representative images of COS7 cells where
the immunological presence of NKCC1a (A) or Rab11 (B) were detected by using primary
antibodies directed against these proteins and developed using secondary antibodies labeled
with Cy3 (NKCC1, red) and FITC (Rab11, green) fluorophores. C. A+B images
superimposed to obtain an overlayed image where colocalization could be estimated as
yellow pixels (red+green). The scale bar shown in the right inferior corner represents 10
µm. D. In silico semiquantitation of red (NKCC1), green (Rab11) and yellow
(NKCC1+Rab11) pixles using Metamorph software suite. Shown are the results obtained
from 10 cells and represented as mean fluorescence intensity in arbitrary units ± SEM. E.
Colocalization heat-map of the squared cell in C computed by using NIH ImageJ.
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ER and Golgi. To support this concept and to visualize the cytoplasmic vesiculated pattern of
NKCC1a location, COS7 cells were treated 5 hs with cycloheximide, a compound produced by
Streptomyces griseus and the most commonly used protein biosynthesis inhibitor (SchneiderPoetsch, et al. 2010). After this period, COS7 cells were fixed and the immunoreactive pattern of
NKCC1a expression visualized by co-immunofluorescence microscopy using antibodies against
NKCC1 and CRT to contrast transporter expression against the ER. As shown in Figure 14,
inhibition of de novo protein synthesis depletes NKCC1a from CRT-positive compartments
providing evidence for the extra-reticular and vesiculated cytoplasmic pattern of NKCC1a
protein expression in these cells.

4.6.

Endogenous NKCC1a locates in medial-Golgi cisternae
Our results suggest that ~50% of endogenous NKCC1a is expressed in COS7 cells as

hybrid-type EndoH-sensitive N-glycosylated proteins (see Fig. 10). Further, hybrid-type Nglycans are synthesized and accumulated in cisternae of the medial-Golgi apparatus (see Fig. 6).
Therefore, we tested whether endogenous NKCC1a and !-mannosidase II (Man2), a medialGolgi resident enzyme (Burke, et al. 1982; Stanley 2011), co-localize in COS7 cells cultured in
the absence or presence of brefeldin A (BFA) a strong inhibitor of the vesicular transport of
cargo proteins from ER to Golgi cisternae and a known disruptor of Golgi integrity (LippincottSchwartz, et al. 1991). As shown in Figure 15A, Man2 labels the typical medial-Golgi structures
in COS7 cells, a pattern that is lost upon treatment with BFA, as expected (Fig. 15D). Similarly,
as shown in Figures 15B and 15C, location of immunoreactive endogenous NKCC1a appears
concentrated towards one of the nuclear poles of the cells i.e., in structures resembling Man2-
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Figure 14. Inhibition of protein synthesis uncovers vesiculated pattern of NKCC1a
expression in COS7 cells. A-B. Shown are representative images of COS7 cells grown in
the presence of cycloheximide (1 µg/ml, 5 hs) to inhibit de novo global protein synthesis
and deplete endogenous NKCC1a from the ER. The immunological presence of NKCC1a
(A) or calreticulin (CRT, B) were detected by using primary antibodies directed against
these proteins and developed using secondary antibodies labeled with Cy3 (red) and FITC
(green) fluorophores. C. A+B images superimposed to obtain an overlayed image where
colocalization could be estimated in heat-maps. The scale bar shown in the left inferior
corner represents 10 µm. D. Colocalization heat-map of the squared cell in C computed by
using NIH ImageJ.
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Figure 15. Endogenous NKCC1a protein localization in medial-Golgi cisternae. Shown
are representative images of COS7 cells grown under control conditions (A-C) or treated 16
hs with 1 µg/ml of brefeldin-A (BFA, D-F). The immunological presence of α-mannosidase
II (A and D) and NKCC1a (B and E) were detected by using primary antibodies directed
against these proteins and developed using secondary antibodies labeled with FITC (green)
and Cy3 (red). C and F. Superimposed images to obtain an overlayed representation of
colocalization between NKCC1a and α-mannosidase II. The scale bar shown in the right
inferior corner represents 10 µm.
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positive compartments. Indeed, as shown in Figures 15C and 15F, a small proportion of
endogenous NKCC1a locates in Man2-positive compartments, a distribution that is lost when
cells were treated with BFA. Therefore, these results support the notion that endogenous
NKCC1a locates in medial-Golgi cisternae.

4.7.

Inhibition of the first step in N-glycan biosynthesis impairs NKCC1a expression
The low abundance of endogenous "mature" NKCC1a protein in the plasma membrane

relative to total core/high-mannose NKCC1a (see Fig. 10) and its defined location in
intracellular compartments strongly suggest that complex N-glycosylation and delivery of the
transporter to the plasma membrane are not related. Thus, to determine the role of Nglycosylation on endogenous NKCC1a trafficking and localization, COS7 cells were first treated
with tunicamycin [TUN (2 !g/ml 16hs)], an inhibitor of the first step of N-glycan biosynthesis
(see Fig. 6). As shown in Figures 16A and 16B, blocking N-glycosylation with TUN resulted in
marked decrease in total immunoreactive NKCC1a protein, a finding consistent with the notion
that core N-glycosylation of proteins plays a fundamental role in protein stability and quality
control in the ER (Aebi 2013; Anelli and Sitia 2008; Breitling and Aebi 2013) and that NKCC1a
is not an exception to this general rule. To add further support to this concept, the
immunological levels of NKCC1a was assayed in Western blots of protein extracts obtained
from COS7 cells cultured 16hs in the presence of 2 !g/ml TUN. As shown in Figures 16C and
16D, TUN treatment of COS7 cells results in a significant reduction in the expression levels of
NKCC1a, in agreement with immunofluorescence data. To correlate the observed drop in total
NKCC1a expression with the plasma membrane levels of the transporter, TUN-treated COS7
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Figure 16. The first step of N-glycan biosynthesis is required for NKCC1a protein expression. A-B. Shown
are representative immunofluorescence microscopy images of COS7 cells grown under control conditions (A) or
treated 16 hs with 2 µg/ml tunicamycin (TUN, B). The immunological presence of NKCC1a was assayed by using
primary antibodies directed against the transporter and developed using FITC-labeled secondary antibodies
(green). C. Representative immunoblot experiment showing total expression levels of endogenous NKCC1a in
COS7 cells grown in the presence of vehicle (DMSO, Control) or TUN 2 µg/ml 16 hs. Note that the expected
bands of ~130 kDa and ~170 kDa are observed in Control cells. As loading control, immunoblots were developed
using antibodies against β-actin. D. Densitometric analysis of total NKCC1a expression levels in immunoblots
from Control and TUN-treated COS7 cells. Results are expressed as the mean ± SEM relative to Control values
(n=3). E. Representative immunoblot experiment demonstrating expression of NKCC1a in total cell extracts and
in the biotinylated plasma membrane fraction purified from COS7 cells treated with TUN. Protein expression of
cytosolic GAPDH was used as a loading control for total protein lysates and to assess the purity of biotinylated
plasma membrane fractions. E. Densitometric analysis of expression levels of core/high-mannose and
hybrid/complex N-glycosylated NKCC1a (~130 kDa and ~170 kDa, respectively) in the biotinylated plasma
membrane fraction of COS7 cells Control or treated with TUN. Results are expressed as the mean ± SEM relative
to the total densitometric signal (130 kDa + 170 kDa) for each treatment (n=3). F. Representative immunoblot
showing the expression pattern of total NKCC1a in COS7 cells in response to TUN (2 µg/ml) during the
indicated periods of time. As loading control, immunoblots were probed against tubulin.
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cells were biotinylated and the plasma membrane fractions purified and subjected to Western
blotting. As shown in Figure 16E, plasma membrane-located NKCC1a decreased after treatment
with TUN in a comparable extent to that of total NKCC1a protein (see Figs. 16C-D), suggesting
that non-N-glycosylated NKCC1a reaches the plasma membrane and that the decrease observed
in this location in response to TUN treatment is due to a decrease in the expression levels of the
transporter rather than inhibition of N-glycosylation. To further verify this notion we tested the
hypothesis that TUN decreases NKCC1a protein expression in a time-dependent fashion taking
advantage the following facts: i) non-glycosylated proteins are usually retained in the ER and
degraded (Anelli and Sitia 2008), and ii) NKCC1 is prone to degradation when destabilized by
truncation or mutagenesis (Nezu et al. 2009). To this end, abundance of NKCC1a protein
expression was determined by immunoblotting protein samples obtained from COS7 cells treated
with 2 !g/ml TUN for 4, 8 and 16 hs. As shown in Figure 16F, TUN resulted in a timedependent reduction in the total expression levels of NKCC1a, suggesting that the first step in Nglycan biosynthesis plays a key role in NKCC1a protein expression.

4.8.

Inhibition of hybrid-type N-glycosylation does not impair plasma membrane targeting
of NKCC1a
The previous results suggest that N-glycosylation of NKCC1a is not required for its

delivery to the plasma membrane. However, these experiments do not discard a role in either
TUN-mediated ER stress or in any additional step of N-glycan processing and maturation i.e.,
the steps beyond the TUN-sensitive one (see Fig. 6) as signals for plasma membrane targeting of
NKCC1a. To determine if N-glycan maturation of endogenous NKCC1a is involved in plasma
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membrane targeting, NKCC1a expression, cellular localization and plasma membrane targeting
were examined in COS7 cells treated 16 hs with kifunensine [KIF (5-10 !g/ml)] an inhibitor of
ER-mannosidase I (Elbein 1984; Elbein, et al. 1990) (see Fig. 6) and hybrid/complex Nglycosylation that does not lead to ER stress (Wang, et al. 2011). As shown in Figure 17A,
inhibition of hybrid-type N-glycan biosynthesis in COS7 cells results in an apparent increase in
core/high-mannose NKCC1a expression, consistent with the fact that inhibition of ERmannosidase I results in the parallel accumulation of high-mannose N-linked proteins in a wide
variety of cells (Elbein et al. 1991; Elbein et al. 1990). To confirm the N-glycan nature of KIFtreated NKCC1a, we tested EndoH-sensitivity of protein extracts obtained from COS7 cells
incubated in the presence of KIF (10 !g/ml, 16hs). As shown in Figure 17B, EndoH treatment
resulted in an almost complete elimination of NKCC1a bands heavier than ~130 kDa in samples
treated with KIF, but not in non-treated control samples where bands of ~170 kDa were still
observed. This finding is consistent with the idea that KIF inhibits complex N-glycosylation of
NKCC1a. Further, EndoH treatment of KIF-treated samples evidenced a slight decrease in
NKCC1a expression (Fig. 17B), in agreement with the proposal that mannosylation of N-glycan
chains in the ER is important for protein stability and quality control (Aebi 2013; Breitling and
Aebi 2013). To determine the impact of KIF on NKCC1a plasma membrane targeting, COS7
cells treated with the drug for 16 hs were biotinylated and labeled plasma membranes purified
and subjected to immunoblotting. As shown in Figure 17C, KIF decreases expression levels of
N-glycosylated NKCC1a without impacting those corresponding to core NKCC1a (~130 kDa)
suggesting that inhibition of hybrid-type N-glycosylation does not impact plasma membrane
location of NKCC1a. However, these results do not invalidate a role of complex N-glycosylation
of NKCC1a in its trafficking to the plasma membrane. In the next Section we address this issue.
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membrane location. A. Representative immunoblot experiment showing total endogenous
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NKCC1a i.e., ~130k Da and ~170 kDa are observed in Control and treated cells whereas
additional immunoreactive NKCC1a bands centered at ~150 kDa are observed only in
protein extracts from KIF-treated cells. As loading control, immunoblots were developed
using antibodies directed aginst β-actin. B. Shown is a representative immunoblot
demonstrating expression of EndoH-sensitive, hybrid-type N-glycosylated NKCC1a in
total extracts of COS7 cells treated with KIF (10 µg/ml 16 hs). Note the absence of
immunoreactive bands correspoinding to NKCC1a ~170 kDa in cell extracts obtained from
KIF-treated cells. C. Shown is a representative immunoblot demonstrating expression of
NKCC1a in biotinylated plasma membrane fractions of COS7 cells grown under control
conditions or treated with KIF (10 µg/ml 16 hs). Protein expression of the cytosolic
GAPDH was used as a loading control for total protein lysates and to assess the purity of
the plasma membrane fractions.

66

4.9.

Inhibition of complex N-glycosylation does not impair plasma membrane targeting of
NKCC1a
To provide evidence in support of the hypothesis that complex N-glycosylation may not

be required for plasma membrane targeting of NKCC1a, the transporter expression was
determined in COS7 cells treated 16hs with swainsonine [SWN (2 !g/ml)], a potent inhibitor of
medial-Golgi Man2 and a known inhibitor of complex N-glycosylation (Elbein et al. 1981; van
den Elsen et al. 2001). Representative results of these experiments are shown in Figure 18A
where blockage of complex-type N-glycan biosynthesis in COS7 cells results in an apparent
increase in precursor core/high-mannose and hybrid-type N-glycosylated NKCC1a expression in
parallel with virtual elimination of complex N-glycosylated NKCC1a (bands of 170 kDa), as
expected for inhibition of Man2 (see Fig. 6). To confirm the N-glycan nature of SWN-treated
NKCC1a, protein extracts of COS7 cells control and treated with SWN were subjected to EndoH
treatment. As shown in Figure 18B, EndoH digestion resulted in a nearly complete elimination
of NKCC1a bands higher than ~130 kDa in samples treated with SWN, but not in control
samples where clear bands of ~170 kDa complex N-glycosylated, EndoH-resistant NKCC1a
proteins are observed thus demonstrating that complex N-glycosylation of NKCC1a is
effectively inhibited by SWN. To determine the impact of SWN on NKCC1a plasma membrane
targeting, COS7 cells treated with the drug for 16 hs were biotinylated and labeled plasma
membranes were purified and subjected to immunoblotting. As shown in Figure 18C, SWN
eliminated complex N-glycosylated NKCC1a in the biotinylated plasma membrane fraction.
However, SWN treatment increased the levels of core/high-mannose and hybrid-type Nglycosylated NKCC1a paralleling the increase in their expression levels. Altogether, these
results points toward the idea that core/high-mannose, hybrid and complex-type NKCC1a
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Figure 18. Inhibition of complex N-glycan biosynthesis does not preclude NKCC1a
plasma membrane location. A. Shown is a representative immunoblot depicting total
endogenous levels of NKCC1a in COS7 cells grown in the presence of vehicle (DMSO,
Control) or swainsonine (SWN, 2 µg/ml 16 hs). Note that the expected bands of ~130 kDa and
~170 kDa are observed in control and treated cells whereas additional bands corresponding to
immunoreactive NKCC1a centered at ~140-160 kDa are observed only in protein extracts
obtained from SWN-treated cells. As loading control, immunoblots were developed using
antibodies directed aginst β-actin. B. Shown is a representative immunoblot demonstrating
EndoH-sensitivity i.e., the hybrid-type N-glycan nature of NKCC1a in total extracts of COS7
cells treated with SWN. Note that no NKCC1a immunoreactive bands of ~170 kDa are
observed in cell extracts obtained from SWN-treated cells. C. Shown is a representative
immunoblot demonstrating expression of NKCC1a in biotinylated plasma membrane
fractions of COS7 cells under control conditions or treated with SWN. Protein expression of
the cytosolic GAPDH was used a loading control for total protein lysates and to assess the
purity of plasma membrane fractions.
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reaches the plasma membrane at levels related to the biosynthetic capacity of the cell rather than
the N-glycan nature of the transporter.
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5. DISCUSSION
NKCC1 co-transporters are ubiquitously distributed in tissues and cell lines (Gamba
2005). However, molecular information of the NKCC1 splice variants expressed is frequently
missing. We show here that NKCC1a is the sole splice variant expressed in COS7 cells. Absence
or undetectable levels of NKCC1b mRNAs is supported by the amplification of single RT-PCR
amplicon obtained by using primer sets designed to co-amplify both, NKCC1a and NKCC1b
mRNAs (Figs. 8A-B) and the exclusive presence of nucleotide sequences corresponding to exon
21 in sequencing chromatograms (data not shown). It has been suggested that the amino acid
sequence encoded by exon 21 in the C-terminus of NKCC1 functions as a sorting signal involved
in targeting of the transporter to the basolateral membrane of polarized cells (Carmosino et al.
2008), a finding inconsistent with the well-known apical location of NKCC1 in polarized cells of
the choroid plexus (Plotkin et al. 1997) and with the fact that some neurons of the dorsal root
ganglion express both NKCC1a and NKCC1b in the plasma membrane (Mao et al. 2012).
Although the mechanisms involved in plasma membrane sorting of proteins in polarized
epithelia have been extensively studied, as stated by Tuma and collaborators, it still remains
unclear to what extent the mechanisms involved in plasma membrane sorting of proteins is
conserved in polarized and non-polarized cells (Tuma, et al. 2002). In fact, non-polarized cells
appear to have the capacity to sort proteins to the plasma membrane, but they do not have the
spatial compartmentalization of polarized cells (Musch, et al. 1996; Yoshimori, et al. 1996).
Therefore, it remains to be determined whether or not NKCC1's cellular fate can be attributed to
differential splicing of exon 21.
The expression of NKCC1a variant at the protein level in COS7 cells was initially
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studied using two different antibodies directed against the transporter i.e., T4 and ckNKCC1
(Figs. 9A-B). The objective of these experiments was to characterize the new commercial
antibody ckNKCC1 and to compare the results with those obtained using T4, a widely-used
monoclonal antibody known to cross-react with NKCC2 (Alvarez-Leefmans 2009), which is
expressed at very low levels in COS7 cells (unpublished results). Our results demonstrate that T4
and ckNKCC1 detect bands of predicted sizes in COS7 and in kidney extracts, the most abundant
source of NKCC2 (Figs. 9A-B). However, contrary to T4, ckNKCC1 did not appear to detect
NKCC2 in the kidney (Fig. 9B), indicating that ckNKCC1 reacts minimally with NKCC2.
Similar results were obtained in immunolocalization experiments using COS7 cells (Figs. 9CD), suggesting that both antibodies could be used to study expression regulation and pattern in
our cell model.
NKCC1 is consistently expressed as an N-glycosylated protein (Alvarez-Leefmans et al.
2001; Gerelsaikhan et al. 2006; Gerelsaikhan and Turner 2000a, b; Marty et al. 2002; Munoz et
al. 2007; Nezu et al. 2009; Parvin et al. 2007; Payne and Forbush 1995; Payne et al. 1995;
Plotkin et al. 1997). In line, our results demonstrate that COS7 cells are not the exception to that
general observation (Fig. 9A). However, regardless of the tissue or species where NKCC1 is
expressed, the two bands of NKCC1 i.e., ~130 kDa and ~170 kDa are considered to represent the
core/high-mannose and complex N-glycosylated versions of the transporter, respectively. This is
based on the ability of PNGaseF to shift NKCC1 expression bands from ~170 kDa to the core
size of ~130 kDa (Alvarez-Leefmans et al. 2001; Marty et al. 2002; Munoz et al. 2007; Nezu et
al. 2009; Payne et al. 2001; Payne et al. 1995; Plotkin et al. 1997). Although our results using
PNGaseF are in agreement with this notion (Fig. 10A), it is clear that PNGaseF cannot
distinguish between hybrid and complex-type N-glycans and therefore, the shift in molecular
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weights observed in the immunoreactive NKCC1 band of ~170 kDa post-PNGaseF treatment
cannot be attributed to complex N-glycans only. Our results establish for the first time that the
broad bands of NKCC1a corresponding to ~170 kDa are highly sensitive to EndoH, suggesting
that most of N-glycosylated NKCC1a is of the hybrid-type (Fig. 10B). In fact, densitometric
analysis of N-glycan bands of NKCC1a before and after PNGaseF treatment resulted in an
almost complete shift of the ~170 kDa N-glycan NKCC1a bands with a concomitant ~2-fold
increase in the densitometric signal of the ~130 kDa bands. The most parsimonious or economic
interpretation of these results is that ~50% of total NKCC1a exist as hybrid/complex-type Nglycan in COS7 cells (Figs. 10C-D). In addition, the results post-EndoH treatment, suggest that
~45% of the total N-glycan load corresponds to the core/high-mannose type and that only ~25%
is of the complex nature i.e., resistant to the action of EndoH (Figs. 10C-D). These results are
consistent with the notion that NKCC1a is expressed in COS7 cells as core/high-mannose and Nglycosylated (hybrid/complex) in a ~1:1 proportion and therefore, the total amount of
endogenous NKCC1a expressed as complex N-glycosylated is far less from that documented in
mammalian cells over-expressing NKCC1 (Nezu et al. 2009). These differences in NKCC1a
behavior when endogenously expressed or when its expression is forced are not out of the
ordinary. Indeed, as mentioned earlier (see Section 1.13) N-glycan biosynthesis depends on the
level and transit of substrate proteins en route to their destination (Stanley 2011). It is
conceivable then that the proportion of complex N-glycosylated NKCC1a may depend on the
amount of precursor protein reaching the appropriate N-glycosylation machinery to reach a given
degree of N-glycan elaboration or decoration to be considered complex N-glycosylated, a task
easily achieved in over-expression experiments.
The prevailing consensus notion determines that complex N-glycosylation is necessary
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for NKCCs to leave the Golgi apparatus and for plasma membrane targeting (Carmosino et al.
2008; Nezu et al. 2009). Among the many molecular signals potentially involved in plasma
membrane targeting of NKCC1, N-glycosylation has indeed been assumed to be one of them
based mainly on the knowledge gathered using two close relatives of NKCC1 i.e., NKCC2 and
NCC (Benziane et al. 2007; Hoover et al. 2003; Paredes et al. 2006). Regardless of the current
view, N-glycosylation may not play a sorting role in NKCC1 targeting the plasma membrane.
Indeed, the N-glycosylation pattern of NKCC1 expression in choroid plexus, where NKCC1 is
clearly apically located (Plotkin et al. 1997), is not different from that of other polarized epithelia
such as the one in the collecting ducts where NKCC1 is clearly basolateral (Kaplan et al. 1996).
In fact, comparable N-glycosylation patterns of NKCC1 protein expression has been described in
many cell lines including T84, HEKs, MDCK, LK-C1 (Payne et al. 2001), the mammalian
central and peripheral nervous systems (Alvarez-Leefmans et al. 2001; Marty et al. 2002; Munoz
et al. 2007; Plotkin et al. 1997), different fish tissues (Horng and Lin 2008; Tipsmark, et al.
2002), urchins (D'Andrea-Winslow, et al. 2001), eels (Tse, et al. 2006) and frogs (AlvarezLeefmans et al. 2001; Jaen, et al. 2011). Furthermore, our plasma membrane biotinylation
experiments performed in COS7 cells revealed the presence of faint levels of complex Nglycosylated NKCC1a (~170 kDa) and much higher levels of core/high-mannose “immature”
NKCC1a (~130 kDa) (Figs. 11A-B). In fact, an estimated 10% of total NKCC1a was present in
the plasma membrane (Fig. 11C), suggesting that a small proportion of total NKCC1a, mostly
core/high-mannose N-glycan, reaches the plasma membrane. In line with this conclusion, most
of endogenous NKCC1a expressed in COS7 cells is located in intracellular compartments (Fig.
11D).
At the functional level, plasma membrane-located NKCC1a appears functional. Indeed,
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COS7 cells uptake Rb+ ions in a BTD-sensitive manner (Fig. 11E) as robustly as other cell lines
in culture such as FHL124, HLE-B3 (Lauf, et al. 2008; Lauf, et al. 2006) or primary cells
(Adragna et al. 2002). These results support the notion that NKCC1a located at the plasma
membrane of which the major proportion is core/high-mannose N-glycosylated is functional in
spite of the fact that complex N-glycosylated NKCC1a was minimally found at the plasma
membrane (Fig. 11A). These results not only contrast the widely-held notion that only complex
N-glycosylated NKCCs are functional but also brings attention to the common assumption that
complex N-glycosylation is necessary for plasma membrane targeting of NKCCs (Benziane et al.
2007; Zaarour et al. 2011; Zaarour et al. 2009; Zaarour et al. 2012). Indeed, ion transporters not
reaching the plasma membrane cannot be functionally assessed, independently of the
mechanisms involved in plasma membrane insertion.
As any polytopic protein, NKCC1a is expected to be present, to some extent, in all
membrane compartments including ER, Golgi cisternae, endosomes and lysosomes. Except for
the lysosomes where we could not find immunoreactive NKCC1a (data not shown), the
transporter was clearly found in CRT-, Rab11- and Man2-positive compartments indicating that
NKCC1a does locate in ER, medial-Golgi and endosomal vesicles (Figs. 12-15). Many studies
demonstrated intracellular localization of endogenous NKCC1 in a wide variety of cells and
tissues such as the parotid and shark rectal glands (Flemmer et al. 2002), neuroendocrine cells
(DeFazio et al. 2002), neuroblasts (Mejia-Gervacio et al. 2011), cells of the collecting ducts of
the kidney (Kaplan et al. 1996), central and peripheral nervous system (Alvarez-Leefmans et al.
2001; Mao et al. 2012) or different polarized and non-polarized cell lines (Alshahrani et al. 2012;
Alshahrani and Di Fulvio 2012; Payne et al. 2001). However, the identities of such intracellular
compartments were not defined. We now extend those results by identifying the organelles
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wherein NKCC1a is located and provide a potential explanation for such localization. Indeed,
the facts that: i) ~25% of total endogenous NKCC1a in complex N-glycosylated (Fig. 10D), ii)
almost 90% of the transporter locates in intracellular compartments whereas ~50% of
endogenous NKCC1a is of the core/high-mannose N-glycan type (Figs. 9C-D and 11D), and iii)
non N-glycosylatable mutants of NKCC2 are retained in the ER and degraded (Zaarour et al.
2009; Zaarour et al. 2012), all indicate that ~50% of NKCC1a may locate in the ER, a prediction
confirmed in our experiments (Fig. 12). However, not all NKCC1a-related immunofluorescence
signal was found in the ER. In fact, ~40% of immunoreactive NKCC1a was dispersed in nonreticular compartments morphologically defined as small vesicles suffused throughout the
cytoplasm or condensed as rings around the nuclei of the cells. This vesiculated distribution in
COS7 cells is typical of the endosomal compartment, in particular the recycling one (LippincottSchwartz et al. 1991). We confirmed localization of endogenous NKCC1a in Rab11-positive
compartments (Fig. 13) suggesting that NKCC1a may traffic from the ER and Golgi to early
endosomes and plasma membrane and back (Ren et al. 1998; Urbe et al. 1993). The vesiculated
pattern of NKCC1a expression in COS7 cells is further evidenced in our experiments showing
depletion of the transporter from ER after protein synthesis inhibition while unmasking its
location in non-reticular vesicles (Fig. 14). These results are in agreement with the notion that
most of endogenous NKCC1a is core/hybrid-type N-glycosylated (Fig. 10D) as this kind of Nglycans are predicted to distribute mainly in ER, cis/medial-Golgi and in endosomal
compartments (Stanley et al. 2009). Following the same reasoning, the very small proportion of
complex N-glycosylated NKCC1a located at the plasma membrane (Fig. 11A) relative to the
estimated ~25% total complex N-glycosylated NKCC1a in COS7 cells (Fig. 10D) together with
the fact that complex N-glycosylation of proteins commences in the medial-Golgi, all predict that
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a small proportion of total endogenous NKCC1a may locate in medial-Golgi cisternae. We have
confirmed this hypothesis by demonstrating co-localization of the transporter with !mannosidase II, a medial-Golgi resident enzyme (van den Elsen et al. 2001), before but not after
BFA-mediated Golgi disruption (Fig. 15). Taken together, these data support the notion that the
N-glycan nature of NKCC1a correlates with the biosynthetic compartmentalization of the
transporter.
Although expected, the abundance of NKCC1a in ER, Golgi and endosomes is
intriguing. As is the case of CFTR, intracellular NKCC1a may play a variety of functions in
vesicle or organelle biology (Bradbury 1999). However, it is also possible that intracellular
NKCC1a may represent an inactive pool of the transporter, which may become available under
certain conditions, as is the case of glucose transporters (Sadler, et al. 2013). Therefore, the
following question arises: is the intracellular pool of NKCC1a regulated? (see next Section 7).
The answer to that question is not simple. We have been arguing that complex N-glycosylation
of NKCC1a may not constitute a sorting signal per se and that the degree of complex Nglycosylation may depend on the protein substrate levels reaching different compartments of the
N-glycosylation machinery in the cell during the biosynthetic pathway, as it is the general case
for all proteins (Stanley 2011). We have addressed this issue by demonstrating that TUN, a
potent inhibitor of the first step of N-glycan biosynthesis significantly reduced total
immunoreactive NKCC1a protein levels (Figs. 16A-D), confirming the notion that core Nglycosylation is important for NKCC1 biosynthesis. Further, the decrease in NKCC1a
expression in TUN-treated cells paralleled the reduced levels of NKCC1a expression at the
plasma membrane (Fig. 16E) suggesting that the decrease in plasma membrane NKCC1a is due
to reduced protein biosynthesis rather than reduced N-glycosylation per se. In other words,
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specific N-glycosylation i.e., N-glycosylation per each mole of NKCC1a protein did not change
upon TUN treatment. Nevertheless, a protein that cannot be N-glycosylated cannot mature and
therefore, the role of N-glycan maturation on plasma membrane targeting cannot be addressed
either by using TUN or by using non-glycosylatable mutants. However, our results demonstrate
the presence of core/high-mannose and much less of complex-type NKCC1a in the plasma
membrane (Fig. 11A) as well as BTD dependent Rb+ uptake (Fig. 11E) indicating that core
“immature” NKCC1a at the membrane might be functional. These results are in harmony with
the studies showing that N-glycosylation does not impact trafficking or functional activity of
transporters such as SLC26A4, some SLC21A human organic solute transporters or SLC26A6
(Azroyan et al. 2011; Dorn, et al. 2009; Soroka, et al. 2008).
Interestingly, complex N-glycosylation of the glucose transporter 4 (GLUT4) is
necessary for its intracellular sequestration preventing the transporter to reach the plasma
membrane (Williams, et al. 2006). Taken together, these results suggest that complex Nglycosylation is not a necessary step for all proteins to reach the plasma membrane. In the case of
NKCC1a, we tested this hypothesis by pharmacologically targeting two key enzymes involved in
N-glycan maturation in COS7 cells: ER-mannosidase I and medial-Golgi !-mannosidase II. Our
results demonstrate that inhibition of ER mannosidase I with KIF increased NKCC1a expression
of the EndoH-sensitive, core/high-mannose type (Figs. 17A-B), as expected for inhibition of ER
mannose trimming and exiting of substrates (Elbein et al. 1991; Elbein et al. 1990). Further, our
results demonstrate that inhibition of ER-mannosidase I decreased the levels of N-glycosylated
NKCC1a in the plasma membrane but not those for core NKCC1a (Fig. 17C) supporting the
notion that hybrid-type N-glycosylation is not required for plasma membrane location of
NKCC1a. This finding does not exclude the possibility that complex N-glycosylation may play a
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role in plasma membrane targeting of NKCC1a. In fact, it has been proposed that it is this step in
N-glycan biosynthesis the one required for Golgi exiting and plasma membrane targeting. We
have confirmed that this is not the case for NKCC1a. Indeed, blocking the first step in complex
N-glycan biosynthesis i.e., inhibition of medial-Golgi !-mannosidase II with SWN prevented
NKCC1a complex N-glycosylation, increased core/high-mannose/hybrid-type N-glycosylated
NKCC1a (Figs. 18A-B) in total cell extracts, as expected, but also at the plasma membrane (Fig.
18C), indicating that NKCC1a biosynthetic expression levels dictates the amount of transporter
in the plasma membrane and not the nature of its N-glycans. Strikingly, similar results have been
demonstrated for other proteins such as the interleukin-2 receptor (Bowlin, et al. 1991; Bowlin
and Sunkara 1988).
In summary, our study is the first to define the intracellular compartments where
endogenous NKCC1a locates in COS7 cells opening the avenue to further determine in more
detail the presence of the transporter in other compartments as well as its regulation. Our studies
will also be helpful to delineate the mechanism involved in NKCC1a trafficking between
different cellular compartments including the plasma membrane. Our results will help in the
design of new strategies aimed at modifying the balance between plasma membrane location and
intracellular compartmentalization of the transporter.
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7. CONCLUSIONS AND FUTURE WORK
The overall objective of this Thesis has been to determine the impact of N-glycosylation
on the fate of NKCC1 endogenously expressed in COS7 cells. Our research provided molecular
evidence that NKCC1a is the sole splice variant of NKCC1 expressed in these cells and that,
contrary to the general consensus notion, a small proportion of endogenous NKCC1a is complex
N-glycosylated. In addition, we showed that most of NKCC1a distributes in intracellular
compartments including the ER, Golgi cisternae and endosomal vesicles, and that an
approximate 5-10% of the total endogenous NKCC1a locates in the plasma membrane in a
functional state. Further, our experiments provided evidence for the first time in support of the
conclusion that plasma membrane location of NKCC1a does not depend on the N-glycan nature
of the transporter but rather on its biosynthetic levels.
The conclusions that could be drawn from the research presented in this Thesis have
raised several questions. For instance: Is NKCC1a function impacted by its N-glycan nature? It
has been argued that only complex N-glycosylated NKCCs are functional once placed in the
plasma membrane. However, our data do not support that conclusion as most if not all plasma
membrane located NKCC1a is of the core/high-mannose N-glycosylated type and NKCC1a
could be measured as BTD-dependent Rb+ fluxes. To partially answer the aforementioned
question, BTD-dependent Rb+ fluxes may be determined in COS7 cells treated with TUN, KIF
or SWN under the conditions described in this Thesis and demonstrated to impact the expression
levels and the N-glycan nature of the transporter. TUN is expected to decrease NKCC1a activity
due to a decrease in the total biosynthetic expression levels of the transporter. However, KIF or
SWN may not impact NKCC1a function. If our hypothesis were correct, complex N-
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glycosylation would be irrelevant for BTD-sensitive Rb+ transport. In fact, increased NKCC1adependent activity may be demonstrated, as we have demonstrated in this Thesis slight upregulation of NKCC1a expression (core/high-mannose and hybrid-type N-glycosylated) at the
plasma membrane after treatment with KIF or SWN.
A second question necessarily follows: Does the N-glycan nature of NKCC1a impact
steady-state cell volume? Although the role of NKCC1 in cell volume regulation is well defined,
BTD-dependent Rb+ fluxes are not necessarily accompanied with changes in cell volume. This is
of relevance as NKCC1 do transport water. Therefore, a similar sets of experiments as those
proposed in the previous paragraph could be performed, being cell volume the variable measured
instead of Rb+ fluxes. If the N-glycan nature of NKCC1a does impact the steady-state cell
volume, changes in this variable should be observed in the absence of altered Rb+ fluxes. Results
like these will open up new lines of research in the field of cell volume regulation and its
involvement in many cellular processes.
A third question raised by our research is related to the fact that most of NKCC1a is
found in intracellular compartments, particularly within the endosomal one: Does this location
represent an inactive pool of the transporter? Clues about this question could be obtained in
COS7 cells challenged with hypertonic solutions and observing how endogenous
immunoreactive NKCC1a distributes in the cell and how much of it may appear in the
biotinylated plasma membrane fraction as a function of time. Should NKCC1a be important to
take this tonic challenge then redistribution of NKCC1a from intracellular compartments to the
plasma membrane should be observed, together with a parallel increase of the transporter in the
plasma membrane fraction. In addition, are these changes potentially dependent upon the postER N-glycan machinery? To delineate the involvement of Golgi-dependent N-glycan complex
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maturation in the potential redistribution of NKCC1a in response to hypertonic challenge,
NKCC1a plasma membrane location could be determined before and after SWN co-treatment.
Inhibition of plasma membrane re-localization upon hypertonic challenge in the presence of
SWN will suggest that complex N-glycosylation of NKCC1a is required for plasma membrane
insertion under hypertonic conditions.
Clearly, more questions related to the impact of N-glycosylation on NKCC1a function
and intracellular trafficking will necessarily rise, as experimental data becomes available in
future experiments.
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